date,username,to,replies,retweets,favorites,text,geo,mentions,hashtags,id,permalink
2020-03-08 18:42:52,DrugsJournal,,0,0,0,"Issue #4 of @DrugsJournal now available including first approval reports on lumateperone (CAPLYTA) in #schizophrenia, lemborexant (DAYVIGO) in #insomnia, avapritinib (AYVAKIET) in GIST and sodium oligomannate in China for #Alzheimers",,@DrugsJournal,#schizophrenia #insomnia #Alzheimers,1236724079048019968,https://twitter.com/DrugsJournal/status/1236724079048019968
2020-03-04 19:50:10,MDEdgePsych,,0,3,3,"On today's Psychcast, Dr. Jonathan Meyer’s is back to teach a #psychiatry Masterclass on Lumateperone for #schizophrenia. Later, Dr. Renee Kohanski goes in-depth about tailored interventions to address #obesity caused by medications. Listen to a preview. http://ms.spr.ly/6015TjESR",,,#psychiatry #schizophrenia #obesity,1235291465779236864,https://twitter.com/MDEdgePsych/status/1235291465779236864
2020-03-04 01:44:34,hitman0307,,0,0,0,"Caplyta 42 mg capsules (lumateperone) will be just over $40 per capsule, making it the most expensive oral antipsychotic on the market, about $2-3/unit more costly than Vraylar (cariprazine) and Latuda (lurasidone). $ITCI",,,,1235018262817185793,https://twitter.com/hitman0307/status/1235018262817185793
2020-03-03 00:45:02,SiteFocusHQ,,0,0,0,"$ITCI Earnings Intelligence Analysis of recent earnings identified Intra-Cellular Therapies Inc (NASDAQ: ITCI ) business focus on (bipolar,bipolar_ii,lumateperone,milligrams), (adjunctive,bipolar,bipolar_ii,lumateperone), (caplyta,medical) https://www.sitefocus.com/cif/ei/cd_itci509420200302",,,,1234640894239727617,https://twitter.com/SiteFocusHQ/status/1234640894239727617
2020-03-02 19:37:00,BrianSkorney,,1,5,16,"Just reading lumateperone FDA review docs and found this gem ""Our only source of reassurance is the fact that a number of drugs, approved for the treatment of schizophrenia and thought to be effective, have similarly failed in adequate and well-controlled studies."" #notreassuring",,,#notreassuring,1234563375767736320,https://twitter.com/BrianSkorney/status/1234563375767736320
2020-03-02 13:42:32,TINMobileNews,,0,0,0,"Intra-Cellular plans to initiate Phase 2 trial of lumateperone in MDD in 2020 (The Fly) http://dlvr.it/RR57nW",,,,1234474171607838720,https://twitter.com/TINMobileNews/status/1234474171607838720
2020-03-02 13:14:29,zbiotech,,0,0,6,"$ITCI 'Subject to the results of Study 402 and our interactions with the FDA regarding our bipolar depression program, in late 2020 we expect to submit a supplemental new drug application (sNDA) to the FDA for regulatory approval for lumateperone for the treatment of BPD'",,,,1234467113030561792,https://twitter.com/zbiotech/status/1234467113030561792
2020-02-24 17:32:02,AdisJournals,,0,1,0,"Read our AdisInsight Report on Lumateperone following its recent FDA approval, briefly reviewing the pharmacological properties, clinical efficacy and tolerability of the agent. Read the article here: https://buff.ly/2T1TGcJ #Schizophrenia",,,#Schizophrenia,1231995212723052544,https://twitter.com/AdisJournals/status/1231995212723052544
2020-02-21 18:24:18,psychopharmacol,,0,0,0,"Lumateperone is a presynaptic D2 partial agonist, like aripiprazol, and a postsynaptic D2 antag. Also, it increased phosphorylation of mesolimbic GluN2Btype NMDA–type glutamate r. that could increase its activity. But, it remains unclear whether this MoA is clinically relevant.",,,,1230921200425144329,https://twitter.com/psychopharmacol/status/1230921200425144329
2020-02-21 18:19:40,psychopharmacol,,1,1,0,"FDA approved Caplyta (lumateperone) to treat schizophrenia in adults. Therapeutic advantages over current medications have not been reported, A ""me-too"" medication? Lumateperone has increased binding at the 5-HT2A r. without excess binding to the D2 r. ",,,,1230920034429612032,https://twitter.com/psychopharmacol/status/1230920034429612032
2020-02-21 13:14:05,OpenOutcrier,,0,0,1,"$ITCI (+3.2% pre) Pivotal Study of CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults Published in JAMA Psychiatry - SI ",,,,1230843131194695680,https://twitter.com/OpenOutcrier/status/1230843131194695680
2020-02-20 22:14:50,otcdynamics,,0,2,1,"$ITCI Pivotal Study of CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults Published in JAMA P https://www.otcdynamics.com/itci-pivotal-study-of-caplyta-lumateperone-for-the-treatment-of-schizophrenia-in-adults-published-in-jama-psychiatry/?utm_campaign=twitter&amp;utm_medium=twitter&amp;utm_source=twitter",,,,1230616830638723072,https://twitter.com/otcdynamics/status/1230616830638723072
2020-02-20 22:05:07,CrweWorld,,0,0,0,"Pivotal Study of CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults Published in JAMA Psychiatry http://crweworld.com/article/news-provided-by-globenewswire/1425943/pivotal-study-of-caplyta-lumateperone-for-the-treatment-of-schizophrenia-in-adults-published-in-jama-psychiatry",,,,1230614385678143489,https://twitter.com/CrweWorld/status/1230614385678143489
2020-02-20 22:01:24,odibro,,0,3,6,"$ITCI Pivotal Study of CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults Published in ⁦@JAMAPsych⁩ https://www.globenewswire.com/news-release/2020/02/20/1988312/0/en/Pivotal-Study-of-CAPLYTA-lumateperone-for-the-Treatment-of-Schizophrenia-in-Adults-Published-in-JAMA-Psychiatry.html",,@JAMAPsych,,1230613446628081665,https://twitter.com/odibro/status/1230613446628081665
2020-02-20 22:00:38,TraderTexMex,,0,0,5,"$ITCI Pivotal Study of CAPLYTA™ (lumateperone) for the Treatment of Schizophrenia in Adults Published in JAMA Psychiatry",,,,1230613256483622912,https://twitter.com/TraderTexMex/status/1230613256483622912
2020-02-17 22:38:29,PubMedTrending,,0,0,0,"Lumateperone: First Approval. Drugs 2020 #PubmedTrending #PubMed https://www.ncbi.nlm.nih.gov/pubmed/32060882",,,#PubmedTrending #PubMed,1229535618629283840,https://twitter.com/PubMedTrending/status/1229535618629283840
2020-02-16 16:05:00,MDEdgePsych,,1,3,6,"JAMA Psychiatry: Lumateperone shows promise as treatment for #Schizophrenia.",,,#Schizophrenia,1229074205276278785,https://twitter.com/MDEdgePsych/status/1229074205276278785
2020-02-16 11:01:05,PaperbirdsN,,0,0,0,"New article: Lumateperone: First Approval. http://link.paperbirds.me/RQ7db8 #alzheimers #neurology",,,#alzheimers #neurology,1228997722889285632,https://twitter.com/PaperbirdsN/status/1228997722889285632
2020-02-07 22:12:39,dtwResearchInc,,0,0,0,"In Q4, Intra-Cellular Therapies Debutes New Website For Caplyta #intracellulartherapies #CAPLYTA #availablemarch2020 #schizophrenia #schizophreniainadults #lumateperone #antiPsychotic #centralNervousSystemDisorder #CNS #newwebsite #q4 #q42019 #dtwmarkethighlight",,,#intracellulartherapies #CAPLYTA #availablemarch2020 #schizophrenia #schizophreniainadults #lumateperone #antiPsychotic #centralNervousSystemDisorder #CNS #newwebsite #q4 #q42019 #dtwmarkethighlight,1225905235442491392,https://twitter.com/dtwResearchInc/status/1225905235442491392
2020-02-01 14:21:01,DrEvgenyLegedin,,8,5,22,"In 28 days, patients with florid psychosis and initial PANSS=90 improved on placebo by 10 points, on a new ""antipsychotic"" lumateperone - by 14 points. Somnolence and sedation may explain 4 point difference. Old cheap benzos can do that... #schizophrenia https://sci-hub.se/10.1001/jamapsychiatry.2019.4379",,,#schizophrenia,1223612220703232000,https://twitter.com/DrEvgenyLegedin/status/1223612220703232000
2020-01-29 18:22:32,Anton_Pearce,,0,0,0,"FDA OKs Lumateperone (Caplyta), First-in-Class for Schizophrenia http://dlvr.it/RP0FXY",,,,1222585836698341377,https://twitter.com/Anton_Pearce/status/1222585836698341377
2020-01-29 18:18:05,jeromeverony,Mad_In_America,3,0,0,"Thorough critique of the $ITCI lumateperone PhIII program. Cautionary note for those buying into the presumed #Schizophrenia breakthrough by $KRTX: PhII data were the result of non-real world conditions (perfect compliance w/ BID given inpatient...), overstating benefit.",,,#Schizophrenia,1222584714772537344,https://twitter.com/jeromeverony/status/1222584714772537344
2020-01-27 17:54:39,twhitfill,,1,0,1,"Is the @US_FDA FDA getting more lax in its approvals? - Spravato (esketamine) approval with just one Ph3 $JNJ - Vyondys 53 murky approval $SRPT - Calpyta (lumateperone) approval with a Ph3 fail $ITCI The (multi) billion $question: what will be the fate of aducanumab? $BIIB",,@US_FDA,,1221854042592366592,https://twitter.com/twhitfill/status/1221854042592366592
2020-01-24 17:18:51,DrDarrenRFlower,,0,2,4,"FDA approves lumateperone (brand name: Caplyta) as an oral, once-a-day treatment for adult #schizophrenia. #drugs #drugdiscovery https://ir.intracellulartherapies.com/news-releases/news-release-details/fda-approves-intra-cellular-therapies-novel-antipsychotic",,,#schizophrenia #drugs #drugdiscovery,1220757872126169088,https://twitter.com/DrDarrenRFlower/status/1220757872126169088
2020-01-24 12:46:09,PsychopharmInst,,0,1,0,"Psychopharm in 2019: Your Ultimate Guide In this podcast episode, we review the major FDA approvals in psychopharmacology for 2019. We explore brexanolone, bremelanotide, the asenapine skin patch, esketamine, cariprazine, and lumateperone. https://psychopharmacologyinstitute.com/publication/psychopharm-in-2019-your-ultimate-guide-2550?utm_medium=Twitter&amp;utm_source=Twitter&amp;utm_campaign=OPC035",,,,1220689242986295296,https://twitter.com/PsychopharmInst/status/1220689242986295296
2020-01-24 09:40:05,johndrummond33,chrisol1,0,0,0,"Even if there was an association between stopping meds and ""relapsing"", it doesn't say anything about the subset that could have recovered without meds. The recent lumateperone trial is interesting on placebo performance.",,,,1220642418497855488,https://twitter.com/johndrummond33/status/1220642418497855488
2020-01-23 14:01:24,PsychiatryAdv,,0,0,0,"#Lumateperone, a #serotonin, #dopamine, and #glutamate #modulator, demonstrated both efficacy and safety in patients with #schizophrenia experiencing an acute exacerbation of #psychosis.",,,#Lumateperone #serotonin #dopamine #glutamate #modulator #schizophrenia #psychosis,1220345792638132226,https://twitter.com/PsychiatryAdv/status/1220345792638132226
2020-01-21 20:25:02,openexcellence,,0,1,1,"A compelling new report from Robert Whitaker at @Mad_In_America examines #lumateperone, a newly approved drug for #schizophrenia. Whitaker tells the story of the drug trials and subsequent FDA approval, calling the entire process a ""charade."" http://ed.gr/b5qqc",,@Mad_In_America,#lumateperone #schizophrenia,1219717561580912641,https://twitter.com/openexcellence/status/1219717561580912641
2020-01-21 15:15:40,TranspariMED,,1,4,8,"Very interesting and detailed criticism of the design of a clinical trial used as basis for FDA approval for the drug #lumateperone (#Caplyta) Comment: Trial designs should be open to public review BEFORE a trial starts, not when it is too late",,,#lumateperone #Caplyta,1219639708176781313,https://twitter.com/TranspariMED/status/1219639708176781313
2020-01-21 15:00:05,TranspariMED,chrisdc77,0,0,1,"Just came across this: https://www.madinamerica.com/2020/01/the-charade-of-new-drug-approvals-for-schizophrenia/ Classic example of concerns about trial design only being flagged post hoc - after the horse has bolted and regulatory approval been given. #lumateperone",,,#lumateperone,1219635786460561422,https://twitter.com/TranspariMED/status/1219635786460561422
2020-01-20 23:16:47,RealJesseLuke,DrWinarick,0,0,1,"If it’s lumateperone you’re thinking of and seeing the ads I’ve been getting then that’s the name of the company. It’s just a new atypical antipsychotic.",,,,1219398395925860352,https://twitter.com/RealJesseLuke/status/1219398395925860352
2020-01-20 14:10:53,KeimWalter,,0,0,2,"The Charade of New Drug Approvals for Schizophrenia By Robert Whitaker -January 19, 2020 December 23, the FDA approved a new drug for schizophrenia, lumateperone, which was said to be a “first-in-class” medication https://www.madinamerica.com/2020/01/the-charade-of-new-drug-approvals-for-schizophrenia/",,,,1219261015906537472,https://twitter.com/KeimWalter/status/1219261015906537472
2020-01-20 12:03:02,medicaldialogs,,0,0,0,"Lumateperone effective and safe treatment option in schizophrenia: JAMA @JAMAPsych #schizophrenia #Lumateperone #JAMAPsychiatry",,@JAMAPsych,#schizophrenia #Lumateperone #JAMAPsychiatry,1219228842373468160,https://twitter.com/medicaldialogs/status/1219228842373468160
2020-01-20 11:30:01,Foods4thebrain,,0,0,0,"An in-depth look at the “evidence” for lumateperone reveals that the clinical testing and approval of this drug is best described as a charade, a game of scientific pretense. https://bit.ly/2G5lZRD #Schizophrenia #mentalhealth #MentalHealthAwareness #brainhealth",,,#Schizophrenia #mentalhealth #MentalHealthAwareness #brainhealth,1219220533654454273,https://twitter.com/Foods4thebrain/status/1219220533654454273
2020-01-19 23:45:52,johndrummond33,TJOttawa,0,0,0,"For antipsychotics, there are zero placebo trials in 1st episode patients. For new approvals like lumateperone, chronic patients are abruptly taken off antipsychotics, before being given the new drug, and they improve either just as much or only 2O% less on placebo.",,,,1219043328509054977,https://twitter.com/johndrummond33/status/1219043328509054977
2020-01-19 21:33:40,ovadosepeace,,0,0,0,"The FDA recently approved lumateperone for schizophrenia. A review of the clinical trials reveals a testing process that is fatally flawed, and a new drug coming to market that doesn't provide a clinically meaningful benefit.https://www.madinamerica.com/2020/01/the-charade-of-new-drug-approvals-for-schizophrenia/?fbclid=IwAR2j--4w0TmkjZPhCb60t8jh-0Z4ZEGUwtG39RCRvtOKxSJXxJzKPrc14yQ",,,,1219010056160571392,https://twitter.com/ovadosepeace/status/1219010056160571392
2020-01-19 19:23:02,Martin_Ploederl,,1,9,14,"Troubling approval procedure for Lumateperone. Hard to believe that evidence from the phase 3 trial, which was based on a discontinuation design, was used so uncritically. Important debunking by Bob Whitaker. https://www.madinamerica.com/2020/01/the-charade-of-new-drug-approvals-for-schizophrenia/",,,,1218977181390557185,https://twitter.com/Martin_Ploederl/status/1218977181390557185
2020-01-19 14:29:29,WordsByFrank,,0,0,0,"The Potential Role of Lumateperone ",,,,1218903308246511622,https://twitter.com/WordsByFrank/status/1218903308246511622
2020-01-19 14:27:07,WordsByFrank,,0,0,0,"Efficacy and Safety of Lumateperone for Treatment of Schizophrenia ",,,,1218902712164605952,https://twitter.com/WordsByFrank/status/1218902712164605952
2020-01-18 14:48:14,GerdnerMD,,0,0,0,"Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial. - PubMed https://www.ncbi.nlm.nih.gov/pubmed/31913424/",,,,1218545637265936385,https://twitter.com/GerdnerMD/status/1218545637265936385
2020-01-17 09:27:32,CNWLlibraries,,0,0,0,"Great article: Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial. http://www.qxmd.com/r/31913424 #ReadByQxMD",,,#ReadByQxMD,1218102542376296449,https://twitter.com/CNWLlibraries/status/1218102542376296449
2020-01-15 15:03:01,PattiDudek,,0,0,0,"FDA Approves Novel Schizophrenia Drug — Lumateperone also in development for other neuropsychiatric disorders ",,,,1217462196692770817,https://twitter.com/PattiDudek/status/1217462196692770817
2020-01-14 18:40:02,DynaMed_EBSCO,,0,0,1,"Lumateperone (Caplyta) @US_FDA approved for #schizophrenia in adults. Find the evidence in DynaMed: https://ebsco.is/DM011320-3 #Psychiatry #MentalHealth",,@US_FDA,#schizophrenia #Psychiatry #MentalHealth,1217154423169961986,https://twitter.com/DynaMed_EBSCO/status/1217154423169961986
2020-01-13 18:30:41,psychopharmacol,,0,0,0,"Lumateperone 42 mg/d (a serotonin, dopamine, and glutamate modulator) reduced the PANSS total score at 28 days more than placebo (LSMD= −4.2; −7.8 to −0.6; ES=−0.3) in patients with schizophrenia. Lumateperone was well tolerated ",,,,1216789679166627840,https://twitter.com/psychopharmacol/status/1216789679166627840
2020-01-13 03:48:12,seemakh89125928,,0,0,0,"The novel antipsychotic lumateperone, significantly improves symptoms in patients with acute exacerbation of schizophrenia without many of the side effects commonly seen with currently available antipsychotics, new phase 3 data suggest. ",,,,1216567596931092480,https://twitter.com/seemakh89125928/status/1216567596931092480
2020-01-13 03:44:00,MedscapePsych,,0,3,19,"New Data: Novel antipsychotic lumateperone significantly improves symptoms in patients with acute exacerbation of #schizophrenia without many of the common side effects. http://ms.spr.ly/6018TkBuy",,,#schizophrenia,1216566540205797376,https://twitter.com/MedscapePsych/status/1216566540205797376
2020-01-13 01:09:00,Medscape,,0,5,7,"New Data: Novel antipsychotic lumateperone significantly improves symptoms in patients with acute exacerbation of schizophrenia without many of the common side effects. http://ms.spr.ly/6017TkBPW",,,,1216527532922691586,https://twitter.com/Medscape/status/1216527532922691586
2020-01-12 01:42:19,SulamanNawaz,byron_creese,0,0,0,"I think the reason is, agitation in Alzheimer is towards the worst end I.e by product of Alzheimer, likely when neurodegenration is at peak. That’s where AD differs (long debated neurodegenerative BS devel) from SZ. Given this there would hben less of hope for Lumateperone for AD",,,,1216173528615092224,https://twitter.com/SulamanNawaz/status/1216173528615092224
2020-01-11 20:19:42,austinaldenlam,,0,0,0,"The Potential Role of Lumateperone—Something Borrowed? Something New? ",,,,1216092342115061762,https://twitter.com/austinaldenlam/status/1216092342115061762
2020-01-11 20:00:00,JAMAPsych,,1,6,4,"What are the clinical implications of #lumateperone for #schizophrenia with a potentially new receptor binding profile? This editorial explores https://ja.ma/39My2RD",,,#lumateperone #schizophrenia,1216087382199603201,https://twitter.com/JAMAPsych/status/1216087382199603201
2020-01-11 13:09:00,MedscapePharm,,0,4,6,"Novel antipsychotic lumateperone significantly improves symptoms in patients with acute exacerbation of schizophrenia without many of the common side effects. http://ms.spr.ly/6015TkBPf",,,,1215983951174610944,https://twitter.com/MedscapePharm/status/1215983951174610944
2020-01-11 12:37:09,shansiddiqi,KJBinSTL,0,0,1,"Clinical wisdom from somebody whose insights may add value to the limited data on lumateperone and parkinsonism... ",,,,1215975934240661505,https://twitter.com/shansiddiqi/status/1215975934240661505
2020-01-10 22:42:48,RealJesseLuke,,0,0,0,"Am I the only one getting a ridiculous amount of ads for lumateperone?!",,,,1215765966665195522,https://twitter.com/RealJesseLuke/status/1215765966665195522
2020-01-10 21:09:40,KJBinSTL,,1,1,1,"My musings on a question I don't have data for: Is lumateperone good for psychosis in Parkinson disease? ",,,,1215742526897950726,https://twitter.com/KJBinSTL/status/1215742526897950726
2020-01-10 17:07:30,content_catcher,,0,0,0,"New Data on First-In-Class Antipsychotic: The novel antipsychotic lumateperone (Caplyta… ",,,,1215681584625541120,https://twitter.com/content_catcher/status/1215681584625541120
2020-01-10 11:00:20,byron_creese,dost_ongur,2,0,0,"Lumateperone for #agitation in #Alzheimers (AD) was canned in 2018. SZ N=450, AD N=360, both 4 weeks. Given A) SZ clinical syndrome better defined than agitation, B) other antipsychotics have small effect in AD, C) placebo effect in AD... was the AD trial ever likely to succeed?",,,#agitation #Alzheimers,1215589183085039616,https://twitter.com/byron_creese/status/1215589183085039616
2020-01-09 17:38:00,MDMagazine,,0,0,0,"In a new study, Lumateperone demonstrated efficacy for improving the symptoms of #schizophrenia and had a favorable safety profile.",,,#schizophrenia,1215326870322974720,https://twitter.com/MDMagazine/status/1215326870322974720
2020-01-09 13:01:20,bs2537,,1,0,1,"$ITCI: Note on probability of success of third Phase 3 trial, ITI-007-402 in bipolar depression for Lumateperone (data in mid 2020) posted: https://rc.seekingalpha.com/group/vasuda-healthcare-analytics?msg=LnAN7zG3LQEcfT6xS",,,,1215257245455249408,https://twitter.com/bs2537/status/1215257245455249408
2020-01-09 07:45:53,drafabianalemos,,0,0,0,"Efficacy and Safety of Lumateperone for Treatment of Schizophrenia https://ja.ma/301aCDx",,,,1215177861860118528,https://twitter.com/drafabianalemos/status/1215177861860118528
2020-01-08 23:21:40,SEPsiq,,0,10,15,"Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial | Psychiatry | ⁦@JAMAPsych⁩ | JAMA Network https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2758022",,@JAMAPsych,,1215050970087989254,https://twitter.com/SEPsiq/status/1215050970087989254
2020-01-08 22:20:57,dost_ongur,,0,9,26,"A new Phase 3 randomized controlled trial on lumateperone for schizophrenia: ",,,,1215035690695704576,https://twitter.com/dost_ongur/status/1215035690695704576
2020-01-08 22:01:51,dtwResearchInc,,0,0,0,"CAPLYTA is now FDA approved for the treatment of schizophrenia For more information: https://dtw.bz/CAPLYTA #intracellulartherapies #CAPLYTA #newdrug #FDAapproved #schizophrenia #schizophreniainadults #lumateperone #antiPsychotic #centralNervousSystemDisorder #CNS",,,#intracellulartherapies #CAPLYTA #newdrug #FDAapproved #schizophrenia #schizophreniainadults #lumateperone #antiPsychotic #centralNervousSystemDisorder #CNS,1215030885302571011,https://twitter.com/dtwResearchInc/status/1215030885302571011
2020-01-08 21:00:20,HealioPsych,,0,0,0,"Results of a randomized clinical trial demonstrated a favorable safety profile and efficacy of lumateperone for patients with schizophrenia. ",,,,1215015403266678790,https://twitter.com/HealioPsych/status/1215015403266678790
2020-01-08 18:00:00,LampeandCompany,,0,0,0,"#FDA approves novel #Schizophrenia drug — Lumateperone also in development for other neuropsychiatric disorders ",,,#FDA #Schizophrenia,1214970021925081089,https://twitter.com/LampeandCompany/status/1214970021925081089
2020-01-08 17:00:02,JAMAPsych,,0,15,15,"In a Phase 3 trial, lumateperone (42mg) demonstrated significant efficacy for improving the symptoms of schizophrenia with a favorable safety profile. https://ja.ma/39PlAQX",,,,1214954931037331457,https://twitter.com/JAMAPsych/status/1214954931037331457
2020-01-06 09:14:19,reesprescribe,,0,1,0,"First in Class Schizophrenia drug Lumateperone (Caplyta) approved by FDA. A Serotonin-Dopamine Activity Modulator (SDAM) once daily oral agent ://www.medscape.com/viewarticle/923046?src=soc_tw_share via @medscape",,@Medscape,,1214112951000555520,https://twitter.com/reesprescribe/status/1214112951000555520
2020-01-03 22:45:07,Carepatron1,,0,0,0,"This week the U.S. Food and Drug Administration (FDA) approved a new drug — Caplyta (lumateperone), which will give people living with schizophrenia a new approach to treatment. It is expected to be available in early 2020. ",,,,1213229830814208002,https://twitter.com/Carepatron1/status/1213229830814208002
2020-01-03 17:20:04,NAMIMinnesota,,0,1,3,"The US Food and Drug Administration (FDA) has approved lumateperone (Caplyta), a novel antipsychotic from Intra-Cellular Therapies, Inc., for the treatment of schizophrenia in adults. ",,,,1213148033061396482,https://twitter.com/NAMIMinnesota/status/1213148033061396482
2020-01-03 15:07:16,halfvietguy,,0,0,0,"FYI. FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults ",,,,1213114609000804353,https://twitter.com/halfvietguy/status/1213114609000804353
2020-01-02 02:48:04,NewExpressNews,,0,0,0,"FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults https://www.winway.me/health-remedies/fda-approves-caplyta-lumateperone-for-the-treatment-of-schizophrenia-in-adults/ via @WinWay Health Blog",,@WINWAY,,1212566195402149888,https://twitter.com/NewExpressNews/status/1212566195402149888
2020-01-02 01:33:12,iamtoyinadesola,,0,0,0,"EverydayHealth: Lumateperone significantly reduces #schizophrenia symptom severity, according to trials https://trib.al/LzlNMck",,,#schizophrenia,1212547357528788993,https://twitter.com/iamtoyinadesola/status/1212547357528788993
2020-01-02 01:10:16,myHealthPal,,0,0,0,"EverydayHealth: Lumateperone significantly reduces #schizophrenia symptom severity, according to trials https://trib.al/LzlNMck",,,#schizophrenia,1212541587059806208,https://twitter.com/myHealthPal/status/1212541587059806208
2020-01-02 01:00:12,EverydayHealth,,0,1,4,"Lumateperone significantly reduces #schizophrenia symptom severity, according to trials https://trib.al/LzlNMck",,,#schizophrenia,1212539051376627713,https://twitter.com/EverydayHealth/status/1212539051376627713
2020-01-01 20:02:38,semodough,,1,0,4,"combo with mood stabilizer) H2:20: Potentially file NDA for lumateperone in bipolar depression",,,,1212464167313121280,https://twitter.com/semodough/status/1212464167313121280
2020-01-01 20:02:38,semodough,,2,4,13,"$ITCI Catalysts Q1:20: Launch of lumateperone in schizophrenia H1:20: Meet with the FDA to discuss the Phase III bipolar depression monotherapy datasets H1:20: Potential Phase I/II ITI-214 data in heart failure Mid-2020: Report Phase III bipolar depression data for lumateperone",,,,1212464165476077568,https://twitter.com/semodough/status/1212464165476077568
2019-12-31 07:37:01,Rx_Ed,,0,1,6,"Lumateperone is a COMBINED modulator of serotonin, dopamine &amp; glutamate used to treat schizophrenia. It exhibits antagonist activity at central 5HT-2A &amp; D2 receptors. It treats both negative &amp; positive symptoms. The most common side effects are sedation &amp; anticholinergic effects. ",,,,1211914137976147968,https://twitter.com/Rx_Ed/status/1211914137976147968
2019-12-29 19:26:59,CURESZorg,,1,0,3,"New drug on the market: lumateperone. #schizophrenia",,,#schizophrenia,1211368032037150720,https://twitter.com/CURESZorg/status/1211368032037150720
2019-12-29 02:32:54,Jetlax,sertraline_,0,0,0,"A podcast review that might help http://psychopharmacologyinstitute.com/publication/psychopharm-in-2019-your-ultimate-guide-2550 No one knows much bout lumateperone, &amp; from little we know there are doubts on the RCT data (passed 2 failed 1) similar to those for intranasal esketamine APA 2017 annual meeting said lumateperone had GluN2B modulation",,,,1211112830725808129,https://twitter.com/Jetlax/status/1211112830725808129
2019-12-29 01:01:00,MedscapePharm,,0,2,8,"FDA approves #lumateperone for treatment of schizophrenia. ",,,#lumateperone,1211089701790199811,https://twitter.com/MedscapePharm/status/1211089701790199811
2019-12-28 11:51:19,HeartIn_net,,0,0,0,"FDA approves lumateperone for treatment of schizophrenia. #fitness #health #training #healthy #healthylifestyle #cardio #healthyliving #healthylife #medicine #healthcare #AI #cardioworkout #cardiologia #cardiology #wearable #cardiovascular #wearabl https://www.medscape.com/viewarticle/923046?src=soc_tw_191226_mscpedt_news_mdscp_schizophrenia&amp;faf=1",,,#fitness #health #training #healthy #healthylifestyle #cardio #healthyliving #healthylife #medicine #healthcare #AI #cardioworkout #cardiologia #cardiology #wearable #cardiovascular #wearabl,1210890973246640128,https://twitter.com/HeartIn_net/status/1210890973246640128
2019-12-28 09:03:57,ApoThera,,0,0,0,"Lumateperone tosylate (Caplyta) has been approved for treating schizophrenia. Drug Information for Lumateperone tosylate (Caplyta) is available on @ApoThera https://apps.apple.com/us/app/apothera/id526613282 #Psychiatry #mentalhealth #mHealth #hcsm #hcsmeu #medschool #medstudenttwitter #medtwitter",,@ApoThera,#Psychiatry #mentalhealth #mHealth #hcsm #hcsmeu #medschool #medstudenttwitter #medtwitter,1210848852393123840,https://twitter.com/ApoThera/status/1210848852393123840
2019-12-28 02:35:02,MDEdgePsych,,0,3,5,"FDA greenlights lumateperone for the treatment of #schizophrenia. http://ms.spr.ly/6016Tn2br",,,#schizophrenia,1210750976719642627,https://twitter.com/MDEdgePsych/status/1210750976719642627
2019-12-27 15:11:35,NowPsych,,0,0,0,"RT PsychiatricNews: The US_FDA this week approved Caplyta (lumateperone), an oral atypical antipsychotic medication to treat #schizophrenia in adults. http://apapsy.ch/blg-fda-caplyta #MentalHealth",,,#schizophrenia #MentalHealth,1210578982363639808,https://twitter.com/NowPsych/status/1210578982363639808
2019-12-27 15:08:49,PsychiatricNews,,0,4,2,"The @US_FDA this week approved Caplyta (lumateperone), an oral atypical antipsychotic medication to treat #schizophrenia in adults. http://apapsy.ch/blg-fda-caplyta #MentalHealth",,@US_FDA,#schizophrenia #MentalHealth,1210578286801281024,https://twitter.com/PsychiatricNews/status/1210578286801281024
2019-12-27 14:41:16,bonnienewman,,0,0,0,"”Clinicians should avoid concomitant use of lumateperone and CYP3A4 inducers including phenobarbital, or moderate to strong CYP3A4 inhibitors such as telithromycin (Ketek), the manufacturer noted.” #psychiatry #mentalhealth #medicine #psychosis #pharmacy",,,#psychiatry #mentalhealth #medicine #psychosis #pharmacy,1210571354254331905,https://twitter.com/bonnienewman/status/1210571354254331905
2019-12-27 09:15:02,kkmaggon,,0,0,0,"FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults http://sco.lt/5UtAvY",,,,1210489251437121536,https://twitter.com/kkmaggon/status/1210489251437121536
2019-12-27 08:07:15,fpizart,Medscape,0,0,0,"Medscape: FDA approves lumateperone for treatment of schizophrenia. http://ms.spr.ly/6011Tn2cb",,,,1210472194649808897,https://twitter.com/fpizart/status/1210472194649808897
2019-12-27 06:31:17,HansBangen,,0,0,0,"FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults ",,,,1210448043234996224,https://twitter.com/HansBangen/status/1210448043234996224
2019-12-26 23:01:00,Medscape,,0,23,45,"FDA approves lumateperone for treatment of schizophrenia. http://ms.spr.ly/6011Tn2cb",,,,1210334727053488128,https://twitter.com/Medscape/status/1210334727053488128
2019-12-26 10:30:10,Dra_TeraizaMesa,,0,0,0,"RT @MedscapePsych: FDA approves lumateperone for treatment of #schizophrenia. http://ms.spr.ly/6014Tn2cC",,@MedscapePsych,#schizophrenia,1210145772081221633,https://twitter.com/Dra_TeraizaMesa/status/1210145772081221633
2019-12-25 21:14:06,luismariani,,0,0,0,"FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults ",,,,1209945436892651521,https://twitter.com/luismariani/status/1209945436892651521
2019-12-25 08:43:25,alessiobiagimd,,0,0,0,"FDA OKs Lumateperone (Caplyta), First-in-Class for Schizophrenia https://www.medscape.com/viewarticle/923046",,,,1209756519983648768,https://twitter.com/alessiobiagimd/status/1209756519983648768
2019-12-25 00:09:30,Tazz67263687,UOADailyTrades,0,0,0,"Itci’s lumateperone with no adcom and delayed pdufa just got approved this week a week prior to pdufa. Anything’s possible",,,,1209627188993183745,https://twitter.com/Tazz67263687/status/1209627188993183745
2019-12-25 00:02:00,Tazz67263687,SolarMelt,0,0,0,"Itci’s lumateperone that was just approved, week prior to pdufa",,,,1209625301149466625,https://twitter.com/Tazz67263687/status/1209625301149466625
2019-12-24 23:18:28,britishroses1,,0,0,0,"FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults ",,,,1209614347917500418,https://twitter.com/britishroses1/status/1209614347917500418
2019-12-24 22:52:10,dwitb,,0,0,0,"FDA OKs Lumateperone (Caplyta), First-in-Class for Schizophrenia https://www.medscape.com/viewarticle/923046?src=soc_tw_share via @medscape",,@Medscape,,1209607728907378689,https://twitter.com/dwitb/status/1209607728907378689
2019-12-24 19:21:36,shamaimri,,0,0,0,"FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults ",,,,1209554736627757056,https://twitter.com/shamaimri/status/1209554736627757056
2019-12-24 18:37:36,DiamonDie,Drugscom,0,0,1,"Lumateperone is somewhat different from other antipsychotics: besides acting on dopamine and serotonin receptors it's also e.g. NMDA/AMPA booster. Well tolerated, appears to improve sleep without residual drowsiness, studied in dementia too. ",,,,1209543664944525312,https://twitter.com/DiamonDie/status/1209543664944525312
2019-12-24 18:29:24,DrugscomNew,,0,3,2,"FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults - ",,,,1209541600097062912,https://twitter.com/DrugscomNew/status/1209541600097062912
2019-12-24 18:29:24,Drugscom,,0,3,1,"FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults - ",,,,1209541599023243264,https://twitter.com/Drugscom/status/1209541599023243264
2019-12-24 15:24:23,ByJoFagg,,0,2,0,"I had a look at Ubrelvy's approval, Biohaven isn't far behind $AGN $BHVN #ubrogepant while @LizVantage delved into the surprising green light for Caplyta #lumateperone $ITCI https://www.evaluate.com/vantage/articles/news/snippets/ubrelvys-winner-not-long https://www.evaluate.com/vantage/articles/news/snippets/intra-cellular-triples-schizophrenia-approval",,@LizVantage,#ubrogepant #lumateperone,1209495040407605249,https://twitter.com/ByJoFagg/status/1209495040407605249
2019-12-24 15:22:50,Cemhri,,0,0,0,"The US Food and Drug Administration (FDA) has approved lumateperone (Caplyta, Intra-Cellular Therapies, Inc) for treatment of schizophrenia in adults. ",,,,1209494650177888256,https://twitter.com/Cemhri/status/1209494650177888256
2019-12-24 15:19:32,DalyMcEverK,,0,0,1,"FDA OKs Lumateperone (Caplyta), First-in-Class for Schizophrenia Has it been determined if #Schizophrenia is acquired, biological, or #genetic, or combo of genetic predisposition augmented by biology or environment? Meds don’t help exogenous causes https://www.medscape.com/viewarticle/923046",,,#Schizophrenia #genetic,1209493820959838209,https://twitter.com/DalyMcEverK/status/1209493820959838209
2019-12-24 15:00:30,PharmacyWeek,,0,0,0,"FDA Approves Lumateperone For Schizophrenia With Boxed Warning Reuters reports the FDA approved Intra-Cellular Therapies Inc.’s Caplyta (lumateperone) “as a once-daily dose of 42 mg” for the treatment of schizophrenia. The company said it plans ... https://buff.ly/2ELHuX5",,,,1209489027944071168,https://twitter.com/PharmacyWeek/status/1209489027944071168
2019-12-24 14:01:00,MedscapePsych,,0,10,31,"FDA approves lumateperone for treatment of #schizophrenia. http://ms.spr.ly/6014Tn2cC",,,#schizophrenia,1209474054975086594,https://twitter.com/MedscapePsych/status/1209474054975086594
2019-12-24 11:20:01,MedPipeline,,0,0,0,"FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults ",,,,1209433541416800256,https://twitter.com/MedPipeline/status/1209433541416800256
2019-12-24 10:06:36,MinSongX,,0,0,0,"Intra-Cellular ends year with OK for schizophrenia drug lumateperone - - pharmaphorum ",,,,1209415068816945157,https://twitter.com/MinSongX/status/1209415068816945157
2019-12-24 10:04:00,pharmaphorum,,0,1,0,"Intra-Cellular Therapies $ITCI rockets 200% after FDA ends speculation about #schizophrenia drug lumateperone prospects and approves the drug https://bit.ly/2ZoLo1E",,,#schizophrenia,1209414413465333760,https://twitter.com/pharmaphorum/status/1209414413465333760
2019-12-24 07:27:44,Jetlax,,1,0,3,"So Lumateperone. Is this 4th generation glutamatergic (among other MOAs) antipsychotic now, then? It failed a phase III trial for bipolar depression, for the record https://www.medscape.com/viewarticle/923046",,,,1209375087826104322,https://twitter.com/Jetlax/status/1209375087826104322
2019-12-24 01:06:03,Dr_Roufy,,0,0,1,"Lumateperone (Caplyta): New Antipsychotic Approved for Schizophrenia ",,,,1209279034162601989,https://twitter.com/Dr_Roufy/status/1209279034162601989
2019-12-23 23:15:01,MDEdgeTweets,,0,0,0,"FDA greenlights lumateperone for the treatment of schizophrenia. http://ms.spr.ly/6014Tn2wA",,,,1209251091856138240,https://twitter.com/MDEdgeTweets/status/1209251091856138240
2019-12-23 23:00:17,NewExpressNews,,0,0,0,"FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults ",,,,1209247383432900609,https://twitter.com/NewExpressNews/status/1209247383432900609
2019-12-23 22:51:21,fdadaily,,0,0,0,"FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults, ,https://fdadaily.com/2019/12/23/fda-approves-caplyta-lumateperone-for-the-treatment-of-schizophrenia-in-adults/",,,,1209245134098972672,https://twitter.com/fdadaily/status/1209245134098972672
2019-12-23 22:39:05,FeedHcp,,0,0,0,"FDA Approves Caplyta (lumateperone) for the Treatment of Schizophrenia in Adults,,https://www.hcpfeed.com/2019/12/23/fda-approves-caplyta-lumateperone-for-the-treatment-of-schizophrenia-in-adults/,",,,,1209242047900798976,https://twitter.com/FeedHcp/status/1209242047900798976
2019-12-23 22:16:43,drhatton,,0,0,1,"#FDAapproves #Caplyta (#lumateperone) for schizophrenia. Do you know how to say the generic name? Lew-mah-TEH-pur-own #pronunciation #PROnounce #ProDataHealth",,,#FDAapproves #Caplyta #lumateperone #pronunciation #PROnounce #ProDataHealth,1209236420914663424,https://twitter.com/drhatton/status/1209236420914663424
2019-12-23 20:55:31,semodough,,1,7,14,"BTIG Intra-Cellular Therapies, Inc. $ITCI, Buy, $73 PT): Caplyta (Lumateperone) Approved in Schizophrenia – Relatively Clean Label Bodes Well for Solid Uptake for Its 1Q20 Launch – Target to $73",,,,1209215986131439620,https://twitter.com/semodough/status/1209215986131439620
2019-12-23 20:06:32,art2i,Investingcom,0,0,0,"Intra-Cellular Therapies $ITCI, a biopharma on CNS disorders, eg. Parkinson's, dementia, schizophrenia, bipolar disorder, autism, etc. $ITCI jumped 200% on FDA approval today of its CAPLYTA®/#Lumateperone for schizophrenia treatment in adults ",,,#Lumateperone,1209203655636746240,https://twitter.com/art2i/status/1209203655636746240
2019-12-23 18:48:22,Health4Soul,,0,0,1,"Intracellular Therapies Inc ($ITCI) who focuses on Central nervous system psychiatric and neurodegenerative disorders was approved by the FDA to release CAPLYTA® (lumateperone) to the market. This news catalyzed a 200%+ gain intra…https://lnkd.in/dpHUt6k",,,,1209183985538084873,https://twitter.com/Health4Soul/status/1209183985538084873
2019-12-23 18:43:38,pharmacopsych,,0,0,1,"Lumateperone (IntraCellular Therapies; Caplyta) has been approved for the treatment of schiphrenia in adults. PANSS Total Score at 4 weeks NNT=20. Common drug related adverse effects are somnolence/sedation (NNH=7.14) and dry mouth (NNH=25). https://ir.intracellulartherapies.com/news-releases/news-release-details/fda-approves-intra-cellular-therapies-novel-antipsychotic",,,,1209182793353162755,https://twitter.com/pharmacopsych/status/1209182793353162755
2019-12-23 18:30:36,semodough,,2,0,7,"Laden $ITCI: Lumateperone (CAPLYTA) Approved; Commercial Launch 1Q20; Buy and PT $58.",,,,1209179516519768064,https://twitter.com/semodough/status/1209179516519768064
2019-12-23 18:25:00,BioPharmaDive,,1,1,2,"Lumateperone, to be sold as Caplyta, had conflicting results in late-stage trials​. Its approval suggests the FDA is using a ""glass half full lens"" to review neuroscience drugs, said one analyst ",,,,1209178104683327490,https://twitter.com/BioPharmaDive/status/1209178104683327490
2019-12-23 17:53:04,BrainSightsApp,,0,0,0,"FDA OKs Lumateperone (Caplyta), First-in-Class for Schizophrenia - Medscape - Neurology via BrainSights for iOS ",,,,1209170067755323392,https://twitter.com/BrainSightsApp/status/1209170067755323392
2019-12-23 17:21:29,LakshmiYatham,,0,1,8,"FDA just approved novel antipsychotic lumateperone for schizophrenia. Bipolar depression is next with one positive trial and the 2nd to be completed soon.",,,,1209162120111116289,https://twitter.com/LakshmiYatham/status/1209162120111116289
2019-12-23 16:37:32,TINMobileNews,,0,0,0,"Stifel sees Intra-Cellulars Lumateperone approval as bullish for CNS stocks (The Fly) http://dlvr.it/RLppTC",,,,1209151061149110272,https://twitter.com/TINMobileNews/status/1209151061149110272
2019-12-23 16:30:40,NASDAQODUK,,0,0,0,"$ITCI Intra-Cellular Therapies announces CAPLYTA (lumateperone) has been approved by the FDA for the treatment of schizophrenia in adults. The Company expects to initiate the commercial launch of CAPLYTA in late Q1 2020. Stock skyrocketed.",,,,1209149332697600002,https://twitter.com/NASDAQODUK/status/1209149332697600002
2019-12-23 16:28:41,FDAadcomm,,0,2,0,"Update: $ITCI PR for #lumateperone: ",,,#lumateperone,1209148833172721666,https://twitter.com/FDAadcomm/status/1209148833172721666
2019-12-23 15:50:27,drfranktarazi,,0,1,4,"A busy day for #FDA! Two big approvals in one day! First $ITCI #Lumateperone for #schizophrenia then #Eisai drug #Dayvigo (#lemborexant) for #insomnia. Lemborexant blocks #orexin receptors OX1 and OX2. 2nd drug approved for insomnia targeting orexin system after $MRK #Belsomra!",,,#FDA #Lumateperone #schizophrenia #Eisai #Dayvigo #lemborexant #insomnia #orexin #Belsomra,1209139210973671424,https://twitter.com/drfranktarazi/status/1209139210973671424
2019-12-23 15:40:05,MarketWN,,0,0,1,"$ITCI News Article - FDA Approves Intra-Cellular Therapies' Novel Antipsychotic, CAPLYTA (lumateperone) for the Treatment of Schizophrenia in Adults https://marketwirenews.com/news-releases/fda-approves-intra-cellular-therapies-novel-antipsyc-8786777563079734.html #GetYourMoneyRight @Doubleozoe @iamcryptomonkey @DekmarTrades $UURAF $ITCI $TAUG",,@Doubleozoe @iamcryptomonkey @DekmarTrades,#GetYourMoneyRight,1209136604331356160,https://twitter.com/MarketWN/status/1209136604331356160
2019-12-23 15:35:27,BiotechAnalysst,,0,1,3,"Stifel Lumateperone Approval Is Bullish for CNS Stocks - $SAGE, $ACAD, $KRTX and (With Caveats) $BIIB All Come to Mind",,,,1209135438998491136,https://twitter.com/BiotechAnalysst/status/1209135438998491136
2019-12-23 15:25:24,ByJoFagg,,0,0,0,"Caplyta/lumateperone FDA approved, $ITCI shares up 169% https://www.globenewswire.com/news-release/2019/12/23/1963993/0/en/FDA-Approves-Intra-Cellular-Therapies-Novel-Antipsychotic-CAPLYTA-lumateperone-for-the-Treatment-of-Schizophrenia-in-Adults.html",,,,1209132907475984385,https://twitter.com/ByJoFagg/status/1209132907475984385
2019-12-23 15:02:47,TraderSara,,0,1,2,"$ITCI FDA Approves Intra-Cellular Therapies' Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults https://pro.benzinga.com/?afmc=5s #daytrade #daytrading #stocks #stockmarketnews #stockstowatch #referrallink",,,#daytrade #daytrading #stocks #stockmarketnews #stockstowatch #referrallink,1209127215218212864,https://twitter.com/TraderSara/status/1209127215218212864
2019-12-23 14:30:23,LentilLover,,0,0,0,"FDA approve Caplyta (lumateperone), for treatment of schizophrenia. ",,,,1209119061164142593,https://twitter.com/LentilLover/status/1209119061164142593
2019-12-23 14:29:14,PearlF,,0,0,0,"CAPLYTA (Lumateperone) originally developed by Bristol Myers Squibb and licensed to Intra-Cellular Therapies in 2005. https://www.alzforum.org/therapeutics/lumateperone",,,,1209118774756069376,https://twitter.com/PearlF/status/1209118774756069376
2019-12-23 14:27:35,jq1234t,bio_clouseau,1,2,3,"FDA concluded aniline metabolites of lumateperone “thought to be responsible for these toxicities were detected in dogs and rats but were not present in humans at quantifiable levels. Based on all the available evidence, these toxicities do not appear to be relevant to humans.” ",,,,1209118357246664704,https://twitter.com/jq1234t/status/1209118357246664704
2019-12-23 14:17:31,syinvesting,,0,2,7,"$ITCI (+110% PM) received FDA approval for Caplyta (lumateperone) for the treatment of #schizophrenia in adults. The Company expects to initiate the commercial launch of Caplyta in late Q1 2020. https://ir.intracellulartherapies.com/news-releases/news-release-details/fda-approves-intra-cellular-therapies-novel-antipsychotic",,,#schizophrenia,1209115825652862976,https://twitter.com/syinvesting/status/1209115825652862976
2019-12-23 13:48:14,NewsQuantified,,0,0,0,"FDA Approves $ITCI Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults, stock surges +100.81% ",,,,1209108456503799808,https://twitter.com/NewsQuantified/status/1209108456503799808
2019-12-23 13:43:10,capital_stellar,,0,0,1,"$ITCI Since FDA approved Lumateperone with the efficacy that it had (poor) then I would expect them to green-light the bipolar indication too. At EV under $1B, this is a really good risk/reward now. Every psychiatrist wants a safer AAP.",,,,1209107181695455232,https://twitter.com/capital_stellar/status/1209107181695455232
2019-12-23 13:27:07,MDMagazine,,0,3,1,"#Breaking: Intra-Cellular Therapies has announced #lumateperone (CAPLYTA) received approval from the FDA for the treatment of #schizophrenia in adults and the company expects the treatment to be available in late Q1 2020.",,,#Breaking #lumateperone #schizophrenia,1209103140135559169,https://twitter.com/MDMagazine/status/1209103140135559169
2019-12-23 13:12:43,GlobalMedEd,,2,10,47,"FDA approves Intra-CellularTherapies #antipsychotic #Caplyta (#lumateperone) for #schizophrenia in adults. Great news for patients!! http://bit.ly/2QbuoHL #nursepractitioner #psychiatry #mh #mhchat #primarycare #familymedicine",,,#antipsychotic #Caplyta #lumateperone #schizophrenia #nursepractitioner #psychiatry #mh #mhchat #primarycare #familymedicine,1209099516743430149,https://twitter.com/GlobalMedEd/status/1209099516743430149
2019-12-23 12:37:28,operatingstock,,1,0,2,"My watch-list for today's session is not finalised, but I will be watching $ITCI. Large gap with news catalyst. ""CAPLYTA® (lumateperone) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of schizophrenia in adults""",,,,1209090646788595716,https://twitter.com/operatingstock/status/1209090646788595716
2019-12-23 12:35:17,otcdynamics,,0,0,0,"$ITCI FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Sc https://www.otcdynamics.com/itci-fda-approves-intra-cellular-therapies-novel-antipsychotic-caplyta-lumateperone-for-the-treatment-of-schizophrenia-in-adults/?utm_campaign=twitter&amp;utm_medium=twitter&amp;utm_source=twitter",,,,1209090097032900608,https://twitter.com/otcdynamics/status/1209090097032900608
2019-12-23 12:21:24,drfranktarazi,,0,1,3,"A new #antipsychotic drug has arrived! #FDA approved $ITCI CAPLYTA® (#lumateperone) for treatment of adult #schizophrenia patients! To be launched in Q1 2020! ",,,#antipsychotic #FDA #lumateperone #schizophrenia,1209086604746403840,https://twitter.com/drfranktarazi/status/1209086604746403840
2019-12-23 12:21:15,hitman0307,,0,0,3,"$ITCI, great news! FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults | Intra-Cellular Therapies Inc. https://ir.intracellulartherapies.com/news-releases/news-release-details/fda-approves-intra-cellular-therapies-novel-antipsychotic",,,,1209086566838284288,https://twitter.com/hitman0307/status/1209086566838284288
2019-12-23 12:11:35,biotechhack,,0,4,4,"FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults $ITCI",,,,1209084130715217921,https://twitter.com/biotechhack/status/1209084130715217921
2019-12-23 12:10:26,Onellymr,,0,0,1,"$ITCI FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults",,,,1209083841861881856,https://twitter.com/Onellymr/status/1209083841861881856
2019-12-23 12:08:06,JacksonJennings,,0,0,0,"FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treat... https://finance.yahoo.com/news/fda-approves-intra-cellular-therapies-115910597.html?soc_src=hl-viewer&amp;soc_trk=tw via @YahooFinance",,@YahooFinance,,1209083253778526215,https://twitter.com/JacksonJennings/status/1209083253778526215
2019-12-23 12:07:51,Trade_The_News,,0,0,1,"$ITCI FDA approves novel Antipsychotic, CAPLYTA (lumateperone) for the Treatment of Schizophrenia in Adults; Expects to initiate commercial launch of CAPLYTA in late 1Q20 (Intra-Cellular Therapies, Inc.) (More at https://www.tradethenews.com/?twtId=11464)",,,,1209083194810814464,https://twitter.com/Trade_The_News/status/1209083194810814464
2019-12-23 12:03:06,WallStSai,WallStSai,1,1,5,"$ITCI FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults ",,,,1209081998578462720,https://twitter.com/WallStSai/status/1209081998578462720
2019-12-23 12:00:41,bear_fuker,,0,0,0,"FDA Approves Intra-Cellular Therapies' Novel Antipsychotic, CAPLYTA(R) (lumateperone) for the Treatment of Schizophrenia in Adults $ITCI",,,,1209081387787128833,https://twitter.com/bear_fuker/status/1209081387787128833
2019-12-23 12:00:06,CrweWorld,,0,0,0,"FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizoph http://crweworld.com/article/news-provided-by-globenewswire/1360149/fda-approves-intra-cellular-therapies-novel-antipsychotic-caplyta-lumateperone-for-the-treatment-of-schizophrenia-in-adults",,,,1209081243435823105,https://twitter.com/CrweWorld/status/1209081243435823105
2019-12-23 11:59:48,IcemanTrading,,0,4,7,"$ITCI FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults",,,,1209081165912715265,https://twitter.com/IcemanTrading/status/1209081165912715265
2019-12-23 11:59:34,TheTradeXchange,,0,0,0,"$ITCI: FDA Approves Intra-Cellular Therapies’ Novel Antipsychotic, CAPLYTA® (lumateperone) for the Treatment of Schizophrenia in Adults",,,,1209081107318226946,https://twitter.com/TheTradeXchange/status/1209081107318226946
2019-12-22 03:42:17,Greg5thTrad,,0,3,3,"#FDA watch this upcoming week: #PDUFA dates arrive for Correvio Pharma $CORV on Kynapid....DURECT $DRRX for Posmir...and Intra-Cellular Therapies $ITCI for lumateperone. S/A Stocks to Watch 12/20 ",,,#FDA #PDUFA,1208593576072007680,https://twitter.com/Greg5thTrad/status/1208593576072007680
2019-12-20 09:35:04,newsfilterio,,0,0,0,"Intra-Cellular Therapies Highlights Lumateperone Presentations at the 58th Annual Meeting of the American College of Neuropsychopharmacology $ITCI",,,,1207957578296115200,https://twitter.com/newsfilterio/status/1207957578296115200
2019-12-14 23:39:40,newsfilterio,,0,0,0,"Intra-Cellular Therapies Highlights Lumateperone Presentations at the 58th Annual Meeting of the American College of Neuropsychopharma.. $ITCI https://newsfilter.io/articles/intra-cellular-therapies-highlights-lumateperone-presentations-at-the-58th-annual-meeting-of-the-ame-5ad51c7dc8345f93a01fefcfad96511b",,,,1205995803078053889,https://twitter.com/newsfilterio/status/1205995803078053889
2019-12-13 21:42:26,schizocidal,,0,0,0,"Intra-Cellular Therapies Highlights Lumateperone Presentations at the 58th Annual Meeting of the American College of Neuropsychopharmacology - BioSpace https://ift.tt/2Plz5zD",,,,1205603913258414080,https://twitter.com/schizocidal/status/1205603913258414080
2019-12-13 04:53:46,newsfilterio,,0,1,0,"Intra-Cellular Therapies perks up on modestly higher volume ahead of a presentation of lumateperone data tomorrow at the American Coll.. $ITCI",,,,1205350072617037824,https://twitter.com/newsfilterio/status/1205350072617037824
2019-12-12 13:39:33,TINMobileNews,,0,0,0,"Intra-Cellular highlights lumateperone data at ACNP annual meeting (The Fly) http://dlvr.it/RL8B3v",,,,1205120003726381056,https://twitter.com/TINMobileNews/status/1205120003726381056
2019-12-12 13:12:26,schizocidal,,0,0,0,"Intra-Cellular Therapies Highlights Lumateperone Presentations at the 58th Annual Meeting of the American College of Neuropsychopharmacology - GlobeNewswire https://ift.tt/2LLXEUj",,,,1205113177178099713,https://twitter.com/schizocidal/status/1205113177178099713
2019-12-12 12:49:34,feed_stocks,,0,0,0,"Intra-Cellular Therapies Highlights Lumateperone Presentations at the 58th Annual Meeting of the American College of Neuropsychopharmacology http://dlvr.it/RL81f2",,,,1205107424266375168,https://twitter.com/feed_stocks/status/1205107424266375168
2019-12-12 12:35:06,CrweWorld,,0,0,0,"Intra-Cellular Therapies Highlights Lumateperone Presentations at the 58th Annual Meeting of the American College of ",,,,1205103782482169856,https://twitter.com/CrweWorld/status/1205103782482169856
2019-12-12 12:33:02,newsfilterio,,0,0,0,"Intra-Cellular Therapies Highlights Lumateperone Presentations at the 58th Annual Meeting of the American College of Neuropsychopharma.. $ITCI https://newsfilter.io/articles/intra-cellular-therapies-highlights-lumateperone-presentations-at-the-58th-annual-meeting-of-the-ame-5ad51c7dc8345f93a01fefcfad96511b",,,,1205103265194504192,https://twitter.com/newsfilterio/status/1205103265194504192
2019-12-11 21:32:10,hitman0307,biotechw2019,1,0,1,"Company has 2 + schizophrenia studies, that’s all they need for approval. The BP depression data mixed but that has 0 to do with the Dec 27th decision on schizophrenia. The lumateperone w lithium or valproic acid study will be tipping point for the BP depression indication Q32020",,,,1204876554448314374,https://twitter.com/hitman0307/status/1204876554448314374
2019-12-11 20:13:30,hitman0307,biotechw2019,2,0,1,"Doesn’t appear to be anything that hasn’t already been released for lumateperone $ITCI",,,,1204856754955341826,https://twitter.com/hitman0307/status/1204856754955341826
2019-12-10 21:43:01,akatr8,,0,0,0,"$ITCI looks positive for its #Lumateperone approval on 27th Dec. The drugs' profile seems to be attracting attention from the international medical world. We may just have the next big thing here :)",,,#Lumateperone,1204516897674448896,https://twitter.com/akatr8/status/1204516897674448896
2019-12-10 15:41:52,newsfilterio,,0,0,0,"Intra-Cellular up 10% ahead of presentation of lumateperone data $ITCI",,,,1204426011556773889,https://twitter.com/newsfilterio/status/1204426011556773889
2019-12-10 15:26:56,MarketCurrents,,0,0,1,"$ITCI - Intra-Cellular up 10% ahead of presentation of lumateperone data https://seekingalpha.com/news/3525176-intra-cellular-up-10-ahead-of-presentation-of-lumateperone-data?source=feed_f&amp;utm_campaign=twitter_automated&amp;utm_content=news&amp;utm_medium=social&amp;utm_source=twitter",,,,1204422249987489792,https://twitter.com/MarketCurrents/status/1204422249987489792
2019-12-09 11:31:42,Bromus93,,0,0,2,"$ITCI Why I see value in this stock: 1. Beautiful ascending triangle 2. Above 50 sma 3. PDUFA is on Dec 27th for Lumateperone 4. MACD long term uptrend and curling 5. Has the letter i twice. I want to have two cats but my curre... https://stocktwits.com/Bromus/message/186225497",,,,1204000665422434305,https://twitter.com/Bromus93/status/1204000665422434305
2019-12-04 13:05:06,CrweWorld,,0,0,0,"Intra-Cellular Therapies to Present Data on Lumateperone and ITI-333 at the 58th Annual Meeting of the American Coll ",,,,1202212230432845825,https://twitter.com/CrweWorld/status/1202212230432845825
2019-11-28 03:44:38,PersimmonTI,,0,1,3,"$ITCI I hope for lumateperone’s FDA approval, but no position, and will not be taking one. This excerpt from recent earning’s CC (and, wish I could hear the original) an example of my reservations: ",,,,1199896859071963138,https://twitter.com/PersimmonTI/status/1199896859071963138
2019-11-22 11:46:18,semodough,,3,2,6,"$ITCI catalysts Dec 27, 2019: Potential approval of lumateperone in schizophrenia and subsequent launch H1:20: Meet with the FDA to discuss the Phase III bipolar depression monotherapy datasets H1:20: Potential Phase I/II ITI-214 data in heart failure",,,,1197843744650924033,https://twitter.com/semodough/status/1197843744650924033
2019-11-19 18:44:05,hitman0307,semodough,0,0,0,"The $ITCI lumateperone bipolar depression results with adjunctive lithium or valproate in Mid 2020 will be very telling if you all can hang on that long.",,,,1196861718657265664,https://twitter.com/hitman0307/status/1196861718657265664
2019-11-19 16:21:31,semodough,,2,1,4,"Speaking of $ITCI huge event Lumateperone action date (PDUFA) for schizophrenia 12-27-19 upcoming $XBI https://twitter.com/zbiotech/status/1196825145379348486",,,,1196825842598531073,https://twitter.com/semodough/status/1196825842598531073
2019-11-19 16:09:26,MysteriousMole1,MedResCol,0,1,0,"Your views on $ITCI lumateperone? They actually have very favorable LT safety data and are pending approval.",,,,1196822799895158790,https://twitter.com/MysteriousMole1/status/1196822799895158790
2019-11-19 16:00:38,MysteriousMole1,Sports_bios,0,0,1,"Even just in schizo, it will take multiple, successful PhIII head-to-head studies against generic seroquel, abilify and possibyl soon $ITCI lumateperone for this to play out in a way that would justify the buying frenzy.",,,,1196820588439969793,https://twitter.com/MysteriousMole1/status/1196820588439969793
2019-11-18 19:49:33,MysteriousMole1,,1,0,1,"As a reminder, $ITCI's PDUFA for lumateperone in schizophrenia is Dec. 27 - a little over a month from now. ",,,,1196515809939599360,https://twitter.com/MysteriousMole1/status/1196515809939599360
2019-11-18 19:47:06,MysteriousMole1,,1,0,0,"If $KRTX BID combo drug's selling point is going to be its ""clean"" safety profile (not as clean as they let on, IMO), they will have to contend with $ITCI's lumateperone, which despite having cleared PhIII and pending approval is trading at a fraction of virtual-only Karuna",,,,1196515190621257728,https://twitter.com/MysteriousMole1/status/1196515190621257728
2019-11-18 18:57:03,jewishbroke,audvin,0,0,0,"Do you have thoughts on Lumateperone?",,,,1196502595843633152,https://twitter.com/jewishbroke/status/1196502595843633152
2019-11-18 18:16:56,TomSilver39,,0,2,9,"Canaccord Catalysts:"" $ACAD: DRP details at CTAD; schizophrenia P3 late-19; $BHVN:GAD late-4Q19/early1Q20; $CRTX: CTAD presentation COR388 (12/7), FDA Type C meeting in 4Q19; $SAGE: MOUNTAIN SAGE-217 in 4Q19; $ITCI: action date for lumateperone 12/27; $VYGR update VY-FXN01 4Q19""",,,,1196492502242480128,https://twitter.com/TomSilver39/status/1196492502242480128
2019-11-06 12:11:08,semodough,,0,0,3,"$ITCI had $255.4 million in cash, which we believe will carry them into 1H 2021. Lumateperone NDA schizophrenia PDUFA on December 27, 2019",,,,1192051789920636928,https://twitter.com/semodough/status/1192051789920636928
2019-11-05 22:30:04,SiteFocusHQ,,0,0,0,"$ITCI Earnings Intelligence Analysis of recent earnings identified Intra-Cellular Therapies Inc (NASDAQ: ITCI ) business focus on (bipolar,lumateperone,monotherapy), (bipolar,lumateperone,schizophrenia), (bipolar,lumateperone,safety) http://www.bizpage.com/2019q3/image/itci.jpg",,,,1191845162546151425,https://twitter.com/SiteFocusHQ/status/1191845162546151425
2019-10-17 00:09:15,JohnPesch1,,0,0,0,"#ITCI could be an interesting play through Q4. Ramping up salesforce for potential launch of lumateperone, which has had a turbulent path trying to get FDA approval.",,,#ITCI,1184622365919076353,https://twitter.com/JohnPesch1/status/1184622365919076353
2019-10-09 19:00:42,bio_clouseau,ReutersBiz,1,0,5,"Somewhat relevant to $ITCI lumateperone and upcoming PDUFA since it reduced prolactin in LT safety study and therefore has a better risk/benefit profile $JNJ",,,,1182007999314976768,https://twitter.com/bio_clouseau/status/1182007999314976768
2019-09-27 12:35:03,TINMobileNews,,0,0,0,"FDA PDUFA Date for Intra-Cellular Lumateperone is September 27, 2019 (The Fly) http://dlvr.it/RF1DyM",,,,1177562294584143872,https://twitter.com/TINMobileNews/status/1177562294584143872
2019-09-10 20:44:00,MaisaCorp,,0,0,0,"$ITCI US Food and Drug Administration told Intra-Cellular Therapies(ITCI) that it would not schedule an advisory committee meeting regarding lumateperone's review of new drug application",,,,1171524748527882240,https://twitter.com/MaisaCorp/status/1171524748527882240
2019-09-10 18:34:05,TINMobileNews,,0,0,0,"JMP Securities sees successful review of Intra-Cellular lumateperone NDA (The Fly) http://dlvr.it/RCrKPY",,,,1171492052325896192,https://twitter.com/TINMobileNews/status/1171492052325896192
2019-09-10 15:47:41,cmencke,,0,1,0,"AwesomeCapital: Intra-Cellular provides lumateperone update https://awesomecapital.blogspot.com/2019/09/intra-cellular-provides-lumateperone.html?spref=tw",,,,1171450178110255104,https://twitter.com/cmencke/status/1171450178110255104
2019-09-10 15:41:03,TINMobileNews,,0,0,0,"Intra-Cellular slide surprising following lumateperone update, says JPMorgan (The Fly) http://dlvr.it/RCqmgz",,,,1171448506407510016,https://twitter.com/TINMobileNews/status/1171448506407510016
2019-09-10 12:50:30,OpenOutcrier,,0,0,0,"$ITCI (-8.0% pre) Intra-Cellular provides lumateperone update - SA ",,,,1171405589634867200,https://twitter.com/OpenOutcrier/status/1171405589634867200
2019-09-10 12:02:26,MarketCurrents,,0,0,1,"$ITCI - Intra-Cellular provides lumateperone update; shares up 6% premarket https://seekingalpha.com/news/3498216-intra-cellular-provides-lumateperone-update-shares-6-percent-premarket?source=feed_f&amp;utm_campaign=twitter_automated&amp;utm_medium=social&amp;utm_source=twitter",,,,1171393489826770945,https://twitter.com/MarketCurrents/status/1171393489826770945
2019-09-10 11:50:33,feed_stocks,,0,0,0,"Intra-Cellular Therapies Provides Lumateperone Regulatory Update ",,,,1171390501917876226,https://twitter.com/feed_stocks/status/1171390501917876226
2019-09-10 11:41:14,JamesEKrause,,0,1,0,"$ITCI reports that the FDA does not plan an AdComm Mtg for the review of Lumateperone. PDUFA date is Dec 27, 2019. ",,,,1171388157998391297,https://twitter.com/JamesEKrause/status/1171388157998391297
2019-09-10 11:39:38,InsiderBiotech,,0,0,1,"The lumateperone Prescription Drug User Fee Act (PDUFA) goal date is December 27, 2019. Additionally, the Company recently submitted to the FDA the results of non-clinical analyses",,,,1171387755034763265,https://twitter.com/InsiderBiotech/status/1171387755034763265
2019-09-10 11:38:51,InsiderBiotech,,1,0,1,"$ITCI announced that the FDA has informed the Company that it does not have plans to schedule an Advisory Committee meeting in connection with its review of the Company’s New Drug Application (NDA) for lumateperone for the treatment of schizophrenia.",,,,1171387557604708352,https://twitter.com/InsiderBiotech/status/1171387557604708352
2019-09-10 11:35:05,CrweWorld,,0,0,0,"Intra-Cellular Therapies Provides Lumateperone Regulatory Update ",,,,1171386609490509824,https://twitter.com/CrweWorld/status/1171386609490509824
2019-09-10 11:30:29,GNWLive,,0,0,0,"Intra-Cellular Therapies Provides Lumateperone Regulatory Update $ITCI http://bit.ly/2LniOrZ",,,,1171385451279613957,https://twitter.com/GNWLive/status/1171385451279613957
2019-08-19 13:01:47,InsiderBiotech,,0,0,3,"If lumateperone goes on to win approval, though, EvaluatePharma expects the drug will rack up annual sales of more than $1.1 billion by 2024.",,,,1163435895707570176,https://twitter.com/InsiderBiotech/status/1163435895707570176
2019-08-19 13:01:29,InsiderBiotech,,1,0,4,"$ITCI ""Intra-Cellular Therapies could be headed for a game-changing year if its schizophrenia drug lumateperone wins FDA approval. EvaluatePharma views lumateperone as the third-biggest potential new drug approval ahead in the back half of 2019. """,,,,1163435819530690562,https://twitter.com/InsiderBiotech/status/1163435819530690562
2019-08-05 13:28:42,IcemanStocks,,0,0,0,"HER: Intra-Cellular (ITCI), up 3% after announcing that it recently met with the FDA and reached agreement to submit additional non-clinical information in connection with the FDA's ongoing review of the company's new drug application, or NDA, for lumateperone for the treatment",,,,1158369236445614080,https://twitter.com/IcemanStocks/status/1158369236445614080
2019-08-05 12:34:08,TINMobileNews,,0,0,0,"Intra-Cellular agrees to submit additional info for NDA review of lumateperone (The Fly) http://dlvr.it/R9hpmD",,,,1158355507314229249,https://twitter.com/TINMobileNews/status/1158355507314229249
2019-08-05 12:12:08,OpenOutcrier,,0,1,2,"$ITCI (+13.4% pre) Intra-Cellular to submit additional preclinical data for lumateperone NDA; FDA action date extended to December 27; shares up 13% premarket - SA ",,,,1158349968496836609,https://twitter.com/OpenOutcrier/status/1158349968496836609
2019-08-05 12:06:36,MarketCurrents,,0,0,0,"$ITCI - Intra-Cellular to submit additional preclinical data for lumateperone NDA; FDA action date extended to December 27; shares up 13% premarket https://seekingalpha.com/news/3486700-intra-cellular-submit-additional-preclinical-data-lumateperone-nda-fda-action-date-extended?source=feed_f",,,,1158348576025542656,https://twitter.com/MarketCurrents/status/1158348576025542656
2019-08-05 11:56:14,InsiderBiotech,,0,0,2,"$ITCI Intra-Cellular Therapies Reached an Agreement with the FDA for the Submission of Additional Non-Clinical Information for NDA Review of Lumateperone, PDUFA Date Extended 3 Months to December 27, 2019",,,,1158345966384271360,https://twitter.com/InsiderBiotech/status/1158345966384271360
2019-08-05 11:45:21,_B_I_O_T_E_C_H_,,0,0,1,"$ITCi INTRA-CELLULAR THERAPIES - DEAL REACHED WITH FDA ON SUBMISSION OF ADDITIONAL NON-CLINICAL INFORMATION FOR NDA REVIEW OF LUMATEPERONE stock up 10%",,,,1158343228145524739,https://twitter.com/_B_I_O_T_E_C_H_/status/1158343228145524739
2019-08-05 11:37:14,BankTheTrade,,0,0,1,"$ITCI(8.16) spiked $2, holding price but thin, on reached agreement to submit additional non-clinical information in connection with the FDA’s ongoing review of the Company’s New Drug application (NDA) for lumateperone for the treatment of schizophrenia.",,,,1158341186895175681,https://twitter.com/BankTheTrade/status/1158341186895175681
2019-08-05 11:32:44,MSollender,,0,0,2,"$ITCI Additional information related to toxicology findings in previous animal studies with the objective to further substantiate the Company’s position that those findings are not relevant to humans due to species specific differences in the metabolism of lumateperone",,,,1158340052453228546,https://twitter.com/MSollender/status/1158340052453228546
2019-08-05 11:32:08,MSollender,,1,0,0,"$ITCI Agreement reached with FDA on submission of additional non-clinical information for NDA review of lumateperone for the treatment of schizophrenia Lumateperone PDUFA goal date extended three months to December 27, 2019 ",,,,1158339901454258178,https://twitter.com/MSollender/status/1158339901454258178
2019-08-05 11:30:53,TraderTexMex,,0,9,6,"$ITCI PDUFA extended to Dec 27th, Agreement reached with FDA on submission of additional non-clinical information for NDA review of lumateperone for the treatment of schizophrenia",,,,1158339589255389184,https://twitter.com/TraderTexMex/status/1158339589255389184
2019-07-31 22:00:20,MDEdgeTweets,,0,0,0,"FDA cancels lumateperone advisory panel. The schizophrenia drug seems to hit snag. https://www.mdedge.com/psychiatry/article/205599/schizophrenia-other-psychotic-disorders/lumateperone-schizophrenia-drug",,,,1156686055564701701,https://twitter.com/MDEdgeTweets/status/1156686055564701701
2019-07-30 21:00:30,MDEdgePsych,,0,2,1,"FDA cancels lumateperone advisory panel. The schizophrenia drug seems to hit snag. https://www.mdedge.com/psychiatry/article/205599/schizophrenia-other-psychotic-disorders/lumateperone-schizophrenia-drug",,,,1156308609703305216,https://twitter.com/MDEdgePsych/status/1156308609703305216
2019-07-30 20:09:06,MC_OptionTrades,,0,0,1,"$ITCI 16-Aug-19 Straddle Implies a ±16.3% move. Jul 31 FDA Advisory Committee Meeting for Lumateperone for the Treatm... https://marketchameleon.com/Overview/ITCI/OptionSummary/",,,,1156295676818546695,https://twitter.com/MC_OptionTrades/status/1156295676818546695
2019-07-27 14:03:09,MarketChmln,,0,0,0,"$ITCI upcoming event July 31: FDA Advisory Committee Meeting for Lumateperone for the Treatment of Schizophreni. Options expiring on August 16 that cover the event have an implied move of ±17.7% https://marketchameleon.com/Overview/ITCI/OptionChain/?e=5270_20190816",,,,1155116418947588096,https://twitter.com/MarketChmln/status/1155116418947588096
2019-07-25 12:34:15,rumorhound,,0,0,1,"Rumor Hound #AI #MnA captured rumor on $ITCI #IntraCellular #Therapeutics on #FDA #AdCom cancellation (https://bit.ly/2yaamF4) #Lumateperone + extended #PDUFA date w/ pot #NDA filing- See",,,#AI #MnA #IntraCellular #Therapeutics #FDA #AdCom #Lumateperone #PDUFA #NDA,1154369270958186497,https://twitter.com/rumorhound/status/1154369270958186497
2019-07-25 02:05:55,Ceazar_Black,,0,1,1,"$ITCI was unequivocal in regards to safety: ""With over 1,500 people exposed to date, lumateperone has been well-tolerated with a safety profile similar to placebo."" ",,,,1154211143130472448,https://twitter.com/Ceazar_Black/status/1154211143130472448
2019-07-24 17:38:12,MaisaCorp,,0,0,0,"$ITCI This information may result in an extension of the Sept. 27 Prescription Drug User Fee Act target action date for the lumateperone NDA.",,,,1154083373175853056,https://twitter.com/MaisaCorp/status/1154083373175853056
2019-07-24 17:32:00,medcitynews,,0,0,0,"Intra-Cellular / $ITCI share price drops after FDA cancels expert panel meeting for #schizophrenia drug #lumateperone ",,,#schizophrenia #lumateperone,1154081811221241858,https://twitter.com/medcitynews/status/1154081811221241858
2019-07-24 17:24:05,hitman0307,,1,1,7,"$ITCI psychiatry needs antipsychotic medications that 1. Work and 2. Have low incidence of weight gain, sedation, and EPS. If lumateperone checks these boxes, that’s a win for patients. Not many existing antipsychotic check those boxes.",,,,1154079819208044547,https://twitter.com/hitman0307/status/1154079819208044547
2019-07-24 16:10:41,WexCapital,agamemnus_dev,2,0,1,"Besides this $ITCI hubbubaloo is all Wall Street. Idiots sitting at screens trading stuff they don’t understand. Go ask docs about Rexulti and if they need more drugs on shelf. Zero will say “oh yeah, we could really use Lumateperone in our “arsenal” of creativity destruction”",,,,1154061347816136705,https://twitter.com/WexCapital/status/1154061347816136705
2019-07-24 15:56:38,biospace,,0,1,2,"Shares of Intra-Cellular Therapies plunged after the company announced the FDA canceled the advisory committee meeting to discuss the company’s New Drug Application for its schizophrenia drug, lumateperone. ",,,,1154057814312140800,https://twitter.com/biospace/status/1154057814312140800
2019-07-24 15:31:06,AndrewE_Dunn,,1,0,3,"I asked $ITCI for clarity on what this means for lumateperone's regulatory timeline and what non-clinical info was submitted. They won't go beyond their initial release for now. Stock down ~35% since FDA cancellation: ",,,,1154051386461605888,https://twitter.com/AndrewE_Dunn/status/1154051386461605888
2019-07-24 13:42:02,Kevin_W81,,0,0,1,"Lumateperone does provide some favorable profile over standard of care Risperidone. For example, you go to doctor for Schizophrenia treatment, they'll prescribe Risperidone which gives you man boobs and makes you gain weight, cholesterol, etc ",,,,1154023940538245120,https://twitter.com/Kevin_W81/status/1154023940538245120
2019-07-24 12:51:34,OpenOutcrier,,1,1,1,"$ITCI (+12.7% pre) Intra-Cellular up 9% premarket on Ad Com update for lumateperone - SA ",,,,1154011239758139400,https://twitter.com/OpenOutcrier/status/1154011239758139400
2019-07-24 11:55:47,fwpharma,,0,1,1,"Advisory committee meeting for Intra-Cellular's lumateperone in schizophrenia cancelled after FDA seeks more information https://www.firstwordpharma.com/node/1654722 $ITCI",,,,1153997200076283904,https://twitter.com/fwpharma/status/1153997200076283904
2019-07-24 11:37:18,Bigapple2la,,0,0,2,"I would be shocked if Lumateperone (aka ITI-007) ever get approved. $ITCI",,,,1153992550618845184,https://twitter.com/Bigapple2la/status/1153992550618845184
2019-07-24 11:25:48,MarketCurrents,,0,0,1,"$ITCI - Intra-Cellular up 9% premarket on Ad Com update for lumateperone https://seekingalpha.com/news/3480695-intra-cellular-9-percent-premarket-ad-com-update-lumateperone?source=feed_f",,,,1153989655378817025,https://twitter.com/MarketCurrents/status/1153989655378817025
2019-07-24 10:37:35,ByMadeleineA,,1,1,1,"$ITCI bouncing back 9% this morning, but it'll need some good news with lumateperone to recover from recent losses. My take on the cancelled ad com via @Vantageanalysis https://bit.ly/2JTX1pG",,@Vantageanalysis,,1153977522314534912,https://twitter.com/ByMadeleineA/status/1153977522314534912
2019-07-24 10:21:01,mic_h_el,,0,0,2,"$ITCI The “new information” might have convinced the FDA to approve lumateperone, thereby making hearing from the advisory panel meeting moot. Without further details, we’re all just guessing, but biotech is never boring. Thoughts by @statnews @adamfeuerstein Do u agree thesis?",,@statnews @adamfeuerstein,,1153973351985160194,https://twitter.com/mic_h_el/status/1153973351985160194
2019-07-24 02:28:55,neuropsychblog,,0,5,3,"FDA cancels panel review of Intra-Cellular’s #schizophrenia drug, causing shares to tumble https://www.statnews.com/2019/07/23/fda-cancels-panel-review-of-intra-cellulars-schizophrenia-drug-causing-shares-to-tumble/ via @statnews #lumateperone",,@statnews,#schizophrenia #lumateperone,1153854545535131648,https://twitter.com/neuropsychblog/status/1153854545535131648
2019-07-24 00:49:31,InsiderBiotech,adamfeuerstein,1,0,2,"The number of antipsychotic drugs had more toxicity in animal models which then weren't confirmed in human models..Lumateperone had some high toxicity in one animal model in the past (preclinical stage) and FDA was asked for confirmation of safety profile in humans..Luma had exce",,,,1153829530882043905,https://twitter.com/InsiderBiotech/status/1153829530882043905
2019-07-24 00:41:09,TINMobileNews,,0,0,0,"Intra-Cellular updates on lumateperone info provided to FDA (The Fly) http://dlvr.it/R8ykrN",,,,1153827422845820929,https://twitter.com/TINMobileNews/status/1153827422845820929
2019-07-24 00:00:07,MSollender,,1,2,1,"$ITCI Provides Update on FDA Advisory Committee Meeting for Lumateperone The Company recently provided additional information to the FDA in response to information requests relating to non-clinical studies. May result in extension of Sept 27 PDUFA date ",,,,1153817097572511747,https://twitter.com/MSollender/status/1153817097572511747
2019-07-23 23:56:50,FDAadcomm,,2,0,1,"FDA cancels Jul 31 adcomm that was scheduled for #lumateperone by Intra-Cellular Therapies, proposed for the treatment of #schizophrenia. $ICTI #PDAC #FDAPDAC https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-31-2019-meeting-psychopharmacologic-drugs-advisory-committee-meeting-announcement-07312019",,,#lumateperone #schizophrenia #PDAC #FDAPDAC,1153816270539644929,https://twitter.com/FDAadcomm/status/1153816270539644929
2019-07-23 23:55:41,feed_stocks,,0,0,0,"Intra-Cellular Therapies Provides Update on FDA Advisory Committee Meeting for Lumateperone for the Treatment of Schizophrenia http://dlvr.it/R8yfZ3",,,,1153815979882717184,https://twitter.com/feed_stocks/status/1153815979882717184
2019-07-23 23:35:08,CrweWorld,,0,0,0,"Intra-Cellular Therapies Provides Update on FDA Advisory Committee Meeting for Lumateperone for the Treatment of Sch http://crweworld.com/article/news-provided-by-globenewswire/1176426/intra-cellular-therapies-provides-update-on-fda-advisory-committee-meeting-for-lumateperone-for-the-treatment-of-schizophrenia",,,,1153810811392946178,https://twitter.com/CrweWorld/status/1153810811392946178
2019-07-23 23:31:59,NewsFromSPI,,0,0,0,"Intra-Cellular Therapies Provides Update on FDA Advisory Committee Meeting for Lumateperone for the Treatment of Schizophrenia http://ow.ly/4j28101GJzc",,,,1153810016056434689,https://twitter.com/NewsFromSPI/status/1153810016056434689
2019-07-23 21:17:06,syinvesting,,0,3,1,"$ITCI down -31.6% after FDA canceled 7/31 Adcom meeting for lumateperone NDA for schizophrenia. FDA said: ""This meeting has been cancelled because of new information regarding the application. The Agency intends to continue evaluating the application...” https://www.statnews.com/2019/07/23/fda-cancels-panel-review-of-intra-cellulars-schizophrenia-drug-causing-shares-to-tumble/",,,,1153776071256371200,https://twitter.com/syinvesting/status/1153776071256371200
2019-07-23 20:10:57,_B_I_O_T_E_C_H_,,0,1,0,"$ICTI #manufacture related ? RBC: Lumateperone AdComm Cancelled; Limited Clarity Though We Note Another (cont) http://tl.gd/n_1sqv5ho",,,#manufacture,1153759425808805889,https://twitter.com/_B_I_O_T_E_C_H_/status/1153759425808805889
2019-07-23 20:05:17,MaisaCorp,,0,0,0,"$ITCI cancelled a meeting scheduled for July 31 to discuss the company's new drug application of lumateperone tosylate capsules for oral administration to treat schizophrenia. Reasons are?",,,,1153757997543411712,https://twitter.com/MaisaCorp/status/1153757997543411712
2019-07-23 19:40:33,MaisaCorp,,1,0,1,"$ITCI cancelled a meeting scheduled for July 31 to discuss the company's new drug application of lumateperone tosylate capsules for oral administration to treat schizophrenia. The stock trading was halted twice due to volatility",,,,1153751776346148864,https://twitter.com/MaisaCorp/status/1153751776346148864
2019-07-23 19:15:22,MarketCurrents,,0,0,1,"$ITCI - Intra-Cellular down 31% on cancellation of Ad Com meeting on lumateperone ",,,,1153745438450712576,https://twitter.com/MarketCurrents/status/1153745438450712576
2019-07-23 18:56:27,dgingery,,0,0,0,"#FDA cancels July 31 Adcom on Intra-Cellular Therapies' lumateperone tosylate, intended for schizophrenia: ",,,#FDA,1153740676846276608,https://twitter.com/dgingery/status/1153740676846276608
2019-07-23 18:54:33,InsiderBiotech,,1,0,2,"Lumateperone shows different safety on animal while it's totally safe in human..recently confirmed in BPD trials ",,,,1153740200457265152,https://twitter.com/InsiderBiotech/status/1153740200457265152
2019-07-23 18:30:14,BioBreakout,,2,0,2,"$ITCI Intra-Cellular Therapies's FDA Panel on lumateperone tosylate was Canceled",,,,1153734080846077952,https://twitter.com/BioBreakout/status/1153734080846077952
2019-07-22 15:13:07,JMac_SI,,1,0,1,"Starting to get a few potential experts for our member requested call on $ITCI before the Lumateperone panel. Aiming to execute before Thursday. https://slingshotinsights.com/projects/1084 #Schizophrenia",,,#Schizophrenia,1153322086708011008,https://twitter.com/JMac_SI/status/1153322086708011008
2019-07-22 09:10:45,adnewstoday,,0,0,0,"We’ve updated one of our resource pages with new information. Take a look: Lumateperone (ITI-007) ",,,,1153230894716661760,https://twitter.com/adnewstoday/status/1153230894716661760
2019-07-15 11:00:10,PharmaScrip,,0,1,0,"Pipeline Watch: Top-Line Phase III Results With Emicizumab, Lumateperone And Dabigatran http://bit.ly/2lx5gQl #PharmaScrip",,,#PharmaScrip,1150721714462056448,https://twitter.com/PharmaScrip/status/1150721714462056448
2019-07-15 08:01:51,schizocidal,,0,0,0,"Intra-Cellular reports mixed data from lumateperone studies - Drug Development Technology ",,,,1150676840476020736,https://twitter.com/schizocidal/status/1150676840476020736
2019-07-12 15:20:29,schizocidal,,0,0,0,"Intra-Cellular reports mixed data from lumateperone studies - Drug Development Technology https://ift.tt/2Jwtr9H",,,,1149700058587303938,https://twitter.com/schizocidal/status/1149700058587303938
2019-07-12 00:00:05,DepressionData,,0,0,0,"New clinical trial for #depression: Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally https://medtally.com/post/lumateperone-monotherapy-for-the-treatment-of-bipolar-depression-conducted-globally-529490",,,#depression,1149468436096901128,https://twitter.com/DepressionData/status/1149468436096901128
2019-07-11 21:30:00,roslynvchand,roslynvchand,1,0,0,"Lumateperone stay skinny and get it up? Man boobs? Ummm, who said that? LOL!!",,,,1149430666221649920,https://twitter.com/roslynvchand/status/1149430666221649920
2019-07-11 11:55:08,rexcannonPhD,,0,0,0,"Intra-Cellular Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression | Intra-Cellular Therapies Inc. 12 points on a depression scale does not suggest improved function of CNS ⁦@realDonaldTrump⁩",,@realDonaldTrump,,1149285995461959680,https://twitter.com/rexcannonPhD/status/1149285995461959680
2019-07-11 10:27:33,schizocidal,,0,0,0,"Intra-Cellular reports mixed data from lumateperone studies - Drug Development Technology https://ift.tt/2Jwtr9H",,,,1149263951747866624,https://twitter.com/schizocidal/status/1149263951747866624
2019-07-10 04:50:22,fdadaily,,0,0,0,"Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression, ,https://fdadaily.com/2019/07/08/intra-cellular-therapies-announces-positive-top-line-results-from-a-phase-3-trial-of-lumateperone-in-patients-with-bipolar-depression/",,,,1148816712055304198,https://twitter.com/fdadaily/status/1148816712055304198
2019-07-09 13:48:40,Biopharma_asia,,0,0,0,"Positive Top-line Results from a Phase 3 Trial of Lumateperone Announced by Intra-Cellular Therapies in Patients with Bipolar Depression - https://biopharma-asia.com/sections/positive-top-line-results-from-a-phase-3-trial-of-lumateperone-announced-by-intra-cellular-therapies-in-patients-with-bipolar-depression/",,,,1148589788506808320,https://twitter.com/Biopharma_asia/status/1148589788506808320
2019-07-09 10:44:51,SaeedBaygi,,0,1,0,"Intra-Cellular reports mixed #data from lumateperone studies Drug Development Technology Intra-Cellular Therapies has announced top-line data from Study 401 and Study 404, of its lumateperone to treat major de... http://twib.in/l/kgLEro69gb8a #ArtificialIntelligence #Privacy #Toronto",,,#data #ArtificialIntelligence #Privacy #Toronto,1148543530220105729,https://twitter.com/SaeedBaygi/status/1148543530220105729
2019-07-09 10:33:50,semodough,,0,0,4,"Laden $ITCI Upcoming Catalysts: The FDA will hold an AdCom meeting for Lumateperone in the treatment for Schizophrenia on July 31, 2019. We see lumateperone’s improved safety profile will support a positive AdCom meeting.",,,,1148540758930182144,https://twitter.com/semodough/status/1148540758930182144
2019-07-09 09:47:05,schizocidal,,0,0,0,"Intra-Cellular reports mixed data from lumateperone studies - Drug Development Technology https://ift.tt/2Jwtr9H",,,,1148528995568431104,https://twitter.com/schizocidal/status/1148528995568431104
2019-07-09 07:01:26,PharmaScrip,,0,0,0,"Intra-Cellular's Lumateperone Brings Mixed Results In Bipolar Depression http://bit.ly/2LMduin #PharmaScrip",,,#PharmaScrip,1148487306011189248,https://twitter.com/PharmaScrip/status/1148487306011189248
2019-07-09 01:03:59,jeff_cranmer,,0,2,2,"$ITCI hopes robust treatment response in one Phase 3 lumateperone trial along w/ lack of tolerable treatment options will be enough to carry bipolar #depression therapy across the goal line at FDA. @EMcCallister01 reports in @BioCentury",,@EMcCallister01 @BioCentury,#depression,1148397353214214144,https://twitter.com/jeff_cranmer/status/1148397353214214144
2019-07-09 00:35:28,cafepharma,,0,0,0,"Intra-Cellular optimistic on lumateperone's future in bipolar despite mixed Phase III results http://tinyurl.com/y5kvog2n",,,,1148390176856690688,https://twitter.com/cafepharma/status/1148390176856690688
2019-07-08 22:30:14,BioCentury,,0,0,2,"Intra-Cellular optimistic on lumateperone's future in bipolar despite mixed Phase III results $ITCI #depression https://buff.ly/2LcyVtl",,,#depression,1148358660030128128,https://twitter.com/BioCentury/status/1148358660030128128
2019-07-08 20:00:01,DDNewsOnline,,0,0,1,"50/50 for Intra-Cellular’s #lumateperone in two Ph3 #clinicaltrials vs #depression in #Bipolar I &amp; II 5-HT2A receptor antagonist hit endpoint in one study; high placebo response in 2nd https://www.intracellulartherapies.com/products-and-technology/lumateperone/ #itci #neuropsychiatric #neurosciences @WCGWorld @BurnsMcClellan",,@WCGWorld @BurnsMcClellan,#lumateperone #clinicaltrials #depression #Bipolar #itci #neuropsychiatric #neurosciences,1148320854473883649,https://twitter.com/DDNewsOnline/status/1148320854473883649
2019-07-08 18:04:12,Briefingcom,,0,0,0,"$SCANX: Small cap notable movers of interest -- Intra-Cellular Therapies (ITCI) falls following Phase 3 lumateperone... http://bit.ly/2LJTqx2",,,,1148291709702270982,https://twitter.com/Briefingcom/status/1148291709702270982
2019-07-08 17:22:53,PsychAnnals,,0,0,1,"Phase 3 data supports #lumateperone for major #depressive episodes associated with #bipolar disorder: https://www.healio.com/psychiatry/bipolar-disorder/news/online/%7Be849adff-1dbf-4f3e-9642-71d78ad12195%7D/phase-3-data-supports-lumateperone-for-bipolar-depression?utm_medium=social&amp;utm_source=twitter&amp;utm_campaign=sociallinks",,,#lumateperone #depressive #bipolar,1148281311594975232,https://twitter.com/PsychAnnals/status/1148281311594975232
2019-07-08 14:25:51,GlobalMedEd,,1,1,3,"#Lumateperone showed efficacy in one of two trials in #bipolar #depression which has great unmet needs.Tolerability was excellent. Negative study had high placebo response rate. http://bit.ly/2YC7Ine #nursepractitioner #mhchat #psychiatry #primarycare #mhsm #familymedicine",,,#Lumateperone #bipolar #depression #nursepractitioner #mhchat #psychiatry #primarycare #mhsm #familymedicine,1148236760738095104,https://twitter.com/GlobalMedEd/status/1148236760738095104
2019-07-08 14:11:19,syinvesting,,0,0,0,"$ITCI (-22% intraday) announced topline results from two Phase 3 trials of lumateperone in bipolar depression. Study 404 met its primary endpoint, while Study 401 did not due to a high placebo response that was observed in the trial. ",,,,1148233102096908289,https://twitter.com/syinvesting/status/1148233102096908289
2019-07-08 13:33:06,womens_womens,,0,2,0,"IntraCellular says ""high placebo response"" to blame as one latestage study fails one succeeds for lumateperone in bipolar depression httpswww.firstwordpharma.comnode1651747Â $ITCI: IntraCellular says ""high placebo response"" to blame as one latestage…",,,,1148223486373974016,https://twitter.com/womens_womens/status/1148223486373974016
2019-07-08 13:19:38,IcemanStocks,,0,0,0,"lumateperone did not its meet primary endpoint... Deutsche Bank (DB), down 5% after announcing it will reduce its workforce by 18,000 employees by 2022 as part of a broad restr",,,,1148220094599708677,https://twitter.com/IcemanStocks/status/1148220094599708677
2019-07-08 13:05:09,Briefingcom,,0,0,0,"$ITCI: Intra-Cellular Therapies announces top-line results from two Phase 3 clinical trials evaluating lumateperone... http://bit.ly/2G2wpBR",,,,1148216453058875392,https://twitter.com/Briefingcom/status/1148216453058875392
2019-07-08 12:49:38,algoally,,0,0,0,"$ITCI - Intra-Cellular Therapies shares are trading lower after the company said its 401 Study of Lumateperone did not meet its primary endpoint. @algoally",,@algoally,,1148212548174401537,https://twitter.com/algoally/status/1148212548174401537
2019-07-08 12:40:07,TINMobileNews,,0,0,0,"Intra-Cellular says Study 401 of lumateperone did not meet primary endpoint (The Fly) http://dlvr.it/R81DbH",,,,1148210152513798144,https://twitter.com/TINMobileNews/status/1148210152513798144
2019-07-08 12:40:07,TINMobileNews,,0,0,0,"Intra-Cellular announces Study 404 of lumateperone met primary endpoint (The Fly) http://dlvr.it/R81DZR",,,,1148210150676680709,https://twitter.com/TINMobileNews/status/1148210150676680709
2019-07-08 12:38:44,OpenOutcrier,,0,0,1,"$ITCI (-15.2% pre) Intra-Cellular down premarket on uneven results from lumateperone studies - SA ",,,,1148209803711406080,https://twitter.com/OpenOutcrier/status/1148209803711406080
2019-07-08 12:37:53,RxRegA,matthewherper,0,0,0,"Adding $ITCI lumateperone for bipolar to #FDAadcommRadar",,,#FDAadcommRadar,1148209590674366464,https://twitter.com/RxRegA/status/1148209590674366464
2019-07-08 12:31:16,drfranktarazi,,0,0,0,"$ITCI #lumateperone Ph 3 trials-mixed results! One hit and one miss in patients with major #depressive episodes associated with #bipolar disorder! $ITCI down!",,,#lumateperone #depressive #bipolar,1148207922448650240,https://twitter.com/drfranktarazi/status/1148207922448650240
2019-07-08 12:18:26,stockspastor,,0,0,0,"Intra-Cellular down 9% premarket on uneven results from lumateperone studies - Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) | Seeking Alpha ⁦@stockspastor⁩ https://seekingalpha.com/news/3476116-intra-cellular-9-percent-premarket-uneven-results-lumateperone-studies",,@stockspastor,,1148204693459542017,https://twitter.com/stockspastor/status/1148204693459542017
2019-07-08 11:54:47,MarketCurrents,,0,0,1,"$ITCI - Intra-Cellular down 9% premarket on uneven results from lumateperone studies https://seekingalpha.com/news/3476116-intra-cellular-9-percent-premarket-uneven-results-lumateperone-studies?source=feed_f",,,,1148198743683899392,https://twitter.com/MarketCurrents/status/1148198743683899392
2019-07-08 11:53:05,ToothFrank,,0,0,1,"$ITCI Intra-Cellular Therapies ( ITCI ) said one phase 3 trial of lumateperone to treat bipolar depression met its primary endpoint while a second phase 3 trial did not.",,,,1148198313445011456,https://twitter.com/ToothFrank/status/1148198313445011456
2019-07-08 11:34:01,fwpharma,,0,0,0,"Intra-Cellular says ""high placebo response"" to blame as one late-stage study fails, one succeeds for lumateperone in bipolar depression https://www.firstwordpharma.com/node/1651747 $ITCI",,,,1148193516830547968,https://twitter.com/fwpharma/status/1148193516830547968
2019-07-08 11:25:24,BioBreakout,,1,0,3,"$ITCI Intra-Cellular Therapies Phase 3 Trial of Lumateperone in Patients with Bipolar Depression Met its Primary Endpoint",,,,1148191349079990272,https://twitter.com/BioBreakout/status/1148191349079990272
2019-07-08 11:13:23,InsiderBiotech,,0,1,2,"$ITCI Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression ",,,,1148188324395401216,https://twitter.com/InsiderBiotech/status/1148188324395401216
2019-07-08 11:06:26,Trade_The_News,,0,0,0,"$ITCI Announces positive top-line results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression (Intra-Cellular Therapies, Inc.) (More at https://www.tradethenews.com/?twtId=8982) umateperone demonstrated a favorable safety profile and was ge",,,,1148186577375567879,https://twitter.com/Trade_The_News/status/1148186577375567879
2019-07-08 11:05:10,semodough,,0,2,3,"$ITCI Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression | Intra-Cellular Therapies Inc. ",,,,1148186255601152001,https://twitter.com/semodough/status/1148186255601152001
2019-07-08 11:05:04,CrweWorld,,0,0,0,"Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with B http://crweworld.com/article/news-provided-by-globenewswire/1156823/intra-cellular-therapies-announces-positive-top-line-results-from-a-phase-3-trial-of-lumateperone-in-patients-with-bipolar-depression",,,,1148186233291411457,https://twitter.com/CrweWorld/status/1148186233291411457
2019-07-08 11:03:10,NewsFromSPI,,0,0,0,"Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression http://ow.ly/eHs4101FhKJ",,,,1148185754973212678,https://twitter.com/NewsFromSPI/status/1148185754973212678
2019-07-08 11:02:57,BioStocks,,1,1,5,"$ITCI study 401, Lumateperone did not separate from placebo. A high placebo response was observed in the trial.",,,,1148185697808998400,https://twitter.com/BioStocks/status/1148185697808998400
2019-07-08 11:01:50,MSollender,,1,0,2,"$ITCI Intra-Cellular Therapies Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression https://www.globenewswire.com/news-release/2019/07/08/1879347/0/en/Intra-Cellular-Therapies-Announces-Positive-Top-line-Results-from-a-Phase-3-Trial-of-Lumateperone-in-Patients-with-Bipolar-Depression.html",,,,1148185418732470273,https://twitter.com/MSollender/status/1148185418732470273
2019-07-08 11:01:17,BioStocks,,1,4,9,"$ITCI Announces Positive Top-line Results from a Phase 3 Trial of Lumateperone in Patients with Bipolar Depression",,,,1148185279481733120,https://twitter.com/BioStocks/status/1148185279481733120
2019-07-03 20:02:05,eturnermd1,,2,0,0,"They wdn't be holding an Advisory Committee meeting unless it wasn't the subject of hype. Sure enough, a quick google search turned up this poster: ""Lumateperone (ITI-007): A Novel Investigational Agent With Broad Therapeutic Potential Across Multiple Neuropsychiatric Disorders"" ",,,,1146509438771027968,https://twitter.com/eturnermd1/status/1146509438771027968
2019-07-03 19:34:17,eturnermd1,,2,0,2,"New drug coming before FDA Psychopharm Drugs Advisory Committee on July 31: lumateperone for schizophrenia. ",,,,1146502440520318976,https://twitter.com/eturnermd1/status/1146502440520318976
2019-06-21 01:44:43,BradHines,zbiotech,0,0,0,"With ITCI, is there a way to determine a coefficient for how the BPD trial effects the stock vs. the lumateperone AdComm coming up? How do we know which one is more important?",,,,1141884619127758853,https://twitter.com/BradHines/status/1141884619127758853
2019-06-13 23:37:58,HottestStockNow,,0,0,1,"FDA panel to discuss $ITCI 's New Drug Application for lumateperone as a treatment of schizophrenia in adults #NDA http://crweworld.com/symbol/ITCI",,,#NDA,1139316009276284928,https://twitter.com/HottestStockNow/status/1139316009276284928
2019-06-13 23:37:42,NewsQuantified,,0,0,1,"$ITCI said that the U.S. FDA will have a Psychopharmacologic Drugs Advisory Committee meeting to be held on July 31 about the NDA for lumateperone with the proposed indication of treatment of schizophrenia in adults. Stock jumps +14.34% #IntraCellular",,,#IntraCellular,1139315940024127489,https://twitter.com/NewsQuantified/status/1139315940024127489
2019-06-13 14:33:04,TINMobileNews,,0,0,0,"Intra-Cellular announces FDA advisory committee meeting for lumateperone NDA (The Fly) http://dlvr.it/R6Y0sh",,,,1139178878772006912,https://twitter.com/TINMobileNews/status/1139178878772006912
2019-06-13 13:18:11,StockNewsWires,,0,0,1,"$ITCI: FDA Ad Com July 31 for Intra-Cellular’s lumateperone in …: https://www.StockNewsWires.com/itci-fda-ad-com-july-31-for-intra-cellulars-lumateperone-in/",,,,1139160036054315009,https://twitter.com/StockNewsWires/status/1139160036054315009
2019-06-13 13:14:54,ToothFrank,,0,0,3,"$ITCI Announces FDA Advisory Committee Meeting to Review the NDA for Lumateperone for the Treatment of Schizophrenia in Adults for July 31, 2019",,,,1139159210443386881,https://twitter.com/ToothFrank/status/1139159210443386881
2019-06-13 13:12:38,eyeonfda,,0,0,1,"#FDA #Psychopharmacologic Drugs Advisory Committee to meet to discuss NDA for lumateperone tosylate capsules for oral administration for treatment of #schizophrenia on 7/31/2019 http://ow.ly/sfoO50uDaHB #AdComm",,,#FDA #Psychopharmacologic #schizophrenia #AdComm,1139158637883117568,https://twitter.com/eyeonfda/status/1139158637883117568
2019-06-13 13:06:20,InsiderBiotech,,0,0,2,"$ITCI FDA has announced a Psychopharmacologic Drugs Advisory Committee meeting to be held on July 31, 2019 to discuss the New Drug Application (NDA) for lumateperone with the proposed indication of treatment of schizophrenia in adults ",,,,1139157051043696640,https://twitter.com/InsiderBiotech/status/1139157051043696640
2019-06-13 13:05:20,DonnaYoungDC,,0,0,1,"#FDA July 31 Psychopharmacologic Drugs Advisory Committee meeting for $ITCI's lumateperone tosylate capsules in schizophrenia https://s3.amazonaws.com/public-inspection.federalregister.gov/2019-12558.pdf #pharma #biotech #schizophrenia",,,#FDA #pharma #biotech #schizophrenia,1139156801960796160,https://twitter.com/DonnaYoungDC/status/1139156801960796160
2019-06-13 13:01:20,yvsx,,0,0,1,"$ITCI NDA for Lumateperone for the Treatment of Schizophrenia in Adults If approved lumateperone could present a meaningful product for the treatment of schizophrenia given relatively benign safety/side effect profile vs. the current standard of care. ",,,,1139155796049178626,https://twitter.com/yvsx/status/1139155796049178626
2019-06-13 13:00:10,CrweWorld,,0,0,0,"Intra-Cellular Therapies Announces FDA Advisory Committee Meeting to Review the NDA for Lumateperone for the Treatme ",,,,1139155500556214273,https://twitter.com/CrweWorld/status/1139155500556214273
2019-06-13 12:58:43,zbiotech,,0,0,2,"$ITCI panel for lumateperone in schizo july 31",,,,1139155134984986624,https://twitter.com/zbiotech/status/1139155134984986624
2019-06-13 12:57:09,NewsFromSPI,,0,0,0,"Intra-Cellular Therapies Announces FDA Advisory Committee Meeting to Review the NDA for Lumateperone for the Treatment of Schizophrenia in Adults http://ow.ly/y9p2101D9UZ",,,,1139154741492178945,https://twitter.com/NewsFromSPI/status/1139154741492178945
2019-06-13 12:55:58,TraderTexMex,,0,0,4,"$ITCI Intra-Cellular Therapies Announces FDA Advisory Committee Meeting to Review the NDA for Lumateperone for the Treatment of Schizophrenia in Adults; July 31st Adcom",,,,1139154443495235584,https://twitter.com/TraderTexMex/status/1139154443495235584
2019-06-13 12:55:56,BioRunUp,,0,1,3,"$ITCI Announces FDA Advisory Committee Meeting to Review the NDA for Lumateperone for the Treatment of Schizophrenia in Adults July 31, 2019",,,,1139154436339580933,https://twitter.com/BioRunUp/status/1139154436339580933
2019-06-13 12:54:45,FDAadcomm,,1,3,1,"FDA schedules Jul 31 adcomm to discuss an NDA for #lumateperone by Intra-Cellular Therapies for the treatment of #schizophrenia. https://s3.amazonaws.com/public-inspection.federalregister.gov/2019-12558.pdf",,,#lumateperone #schizophrenia,1139154137298460672,https://twitter.com/FDAadcomm/status/1139154137298460672
2019-06-11 17:47:24,InsiderBiotech,Bull56880405,0,1,2,"Lumateperone is the best for Schizo in terms of efficacy + highest safety profile..this indication itself can generate the cashflow enough to multiply $ITCI current price, Bipolar if succeeds will make it fly",,,,1138503011532255232,https://twitter.com/InsiderBiotech/status/1138503011532255232
2019-06-09 13:44:20,Sports_bios,,1,0,0,"$ITCI - what say you about the pending two Phase 3 with Lumateperone on bipolar",,,,1137717063336828934,https://twitter.com/Sports_bios/status/1137717063336828934
2019-05-28 12:26:37,MDMagazine,,0,0,0,"A study presented at #APA2019 found that patients receiving lumateperone saw clinically significant improvements in their #schizophrenia symptoms.",,,#APA2019 #schizophrenia,1133348853082673152,https://twitter.com/MDMagazine/status/1133348853082673152
2019-05-20 13:27:13,Sunshinechem_WH,,0,0,0,"Wuhan Sun-shine Bio-technology hot offers on May: Darolutamide Lasmiditan Maribavi Lumateperone&#13;Relugolix&#13;Vadadustat&#13;Selinexor&#13;Nilotinib&#13;Finerenone&#13;Darolutamide&#13;Lasmiditan&#13;Maribavi Please let me know in time if you need . Merry Email: marketing@sun-shinebio.com;",,,,1130465000521289729,https://twitter.com/Sunshinechem_WH/status/1130465000521289729
2019-05-15 14:58:45,DataTrials,,0,0,2,"$ITCI Phase 3 Lumateperone Monotherapy for the Treatment of Bipolar Depression Conducted Globally… Estimated Primary Completion Date - 06/2019",,,,1128676096889765888,https://twitter.com/DataTrials/status/1128676096889765888
2019-05-15 12:46:49,InsiderBiotech,,1,1,5,"$ITCI Intra-Cellular Therapies Announces Presentations on Lumateperone Schizophrenia Program at the American Psychiatric Association (APA) Annual Meeting in San Francisco, May 18-22, 2019 ",,,,1128642892396933120,https://twitter.com/InsiderBiotech/status/1128642892396933120
2019-05-14 15:04:51,InsiderBiotech,,0,0,4,"$NERV redout - another opportunity for $ITCI Lumateperone which has potential to be blockbuster in mid-term future without strong competitors: ",,,,1128315240695959553,https://twitter.com/InsiderBiotech/status/1128315240695959553
2019-05-08 22:44:19,SiteFocusHQ,,0,0,1,"$ITCI Qualitative Analysis of recent earnings identified Intra-Cellular Therapies Inc (NASDAQ: ITCI ) business focus on (lumateperone,product,safety), (lumateperone,san_francisco), (cash,lumateperone) https://www.sitefocus.com/cif/cifqbainq?ajencparm=Y0ngTYu0J%2F7g2sQFbLYSd3ePUn07RrMwwCOam2WTe3yquQKbpO0Lhb5cSyXSegwF1gikJPrZq5TNsgZ1dgBrEXK5PgdN",,,,1126256545740673024,https://twitter.com/SiteFocusHQ/status/1126256545740673024
2019-04-29 14:20:43,InsiderBiotech,,2,1,4,"$ITCI is my suggestion for long-term portfolio. 355M$cash. They have a robust platform and lead candidate in late-stage: Lumateperone is the first antipsychotic with the nice safety profile, and perspective of broad use even out of antipsychotic market ",,,,1122868316048101381,https://twitter.com/InsiderBiotech/status/1122868316048101381
2019-04-22 17:00:55,bs2537,,0,0,1,"New trade idea posted: Intracellular Therapies' Phase 3 Data For Lumateperone For Bipolar Depression In April: An Options Strategy For Playing This Binary Event. https://www.vhaonline.net/",,,,1120371916706070530,https://twitter.com/bs2537/status/1120371916706070530
2019-04-20 20:52:02,semodough,semodough,0,2,2,"LR $ITCI FDA approval still high risk,given high failure rates in bipolar depression clinical trials among other factors,lumateperone good chance of working in additional (beyond schizophrenia) mood disorders (bipolar depression, major depressive disorder) to get a broad label. ",,,,1119705303619076096,https://twitter.com/semodough/status/1119705303619076096
2019-04-20 20:50:51,semodough,,0,1,4,"$ITCI Management expects to report Lumateperone Phase III data from two monotherapy studies (Study 401 and 404) in bipolar depression in a simultaneous release in 2Q19.",,,,1119705006507270144,https://twitter.com/semodough/status/1119705006507270144
2019-04-15 12:57:23,OpenOutcrier,,0,0,2,"$ITCI (+0.0% pre) Intra-Cellular Therapies presents additional results on Lumateperone at 2019 Congress of SIRS ",,,,1117773917526077443,https://twitter.com/OpenOutcrier/status/1117773917526077443
2019-04-15 12:24:06,MarketCurrents,,0,0,1,"$ITCI - Intra-Cellular Therapies presents additional results on Lumateperone at 2019 Congress of SIRS https://seekingalpha.com/news/3450589-intra-cellular-therapies-presents-additional-results-lumateperone-2019-congress-sirs?source=feed_f",,,,1117765541228187650,https://twitter.com/MarketCurrents/status/1117765541228187650
2019-04-15 11:34:34,TINMobileNews,,0,0,0,"Intra-Cellular presents additional results from lumateperone study at SIRS (The Fly) http://dlvr.it/R2rKv6",,,,1117753074871701504,https://twitter.com/TINMobileNews/status/1117753074871701504
2019-04-15 11:10:29,CrweWorld,,0,0,0,"Intra-Cellular Therapies Presents Additional Results From Long-term Open Label Safety Study of Lumateperone at the 2 ",,,,1117747012550582273,https://twitter.com/CrweWorld/status/1117747012550582273
2019-04-09 12:10:21,CrweWorld,,0,0,0,"Intra-Cellular Therapies Announces Presentation of Lumateperone Long-term Open Label Safety Study at the 2019 Congre ",,,,1115587754014810112,https://twitter.com/CrweWorld/status/1115587754014810112
2019-04-04 11:47:41,BleugoIG,,0,0,0,"$ITCI interesting that there isn’t a branded name for Lumateperone yet.",,,,1113770106956517377,https://twitter.com/BleugoIG/status/1113770106956517377
2019-04-03 20:40:57,semodough,,1,2,5,"$ITCI Management expects to report Lumateperone Phase III data from two monotherapy studies (Study 401 and 404) in bipolar depression in a simultaneous release in 2Q19.",,,,1113541923950813184,https://twitter.com/semodough/status/1113541923950813184
2019-03-30 06:28:02,hgarekar,,0,0,0,"ITI-007 - #Lumateperone, (partial agonist - pre synaptic), looks like its going the #Lurasidone route. Effectiveness comparable to others in #Schizophrenia, less side effects, now being tried for #bipolardepression",,,#Lumateperone #Lurasidone #Schizophrenia #bipolardepression,1111877728427479040,https://twitter.com/hgarekar/status/1111877728427479040
2019-03-16 13:53:17,semodough,,1,2,3,"RBC Battle of the Binaries"" - $ITCI vs. $BCRX. Both companies have important binary events expected in 2Q for their lead assets - we expect ITCI to report both studies of lumateperone in BPD, while BCRX should have ph.III APeX-2 data for BCX7353 in HAE prophylaxis.",,,,1106916347886399488,https://twitter.com/semodough/status/1106916347886399488
2019-03-02 19:09:50,semodough,,0,0,3,"$ITCI catalysts on lumateperone could potentially serve as significant catalysts September 27, 2019 lumateperone NDA PDUFA date for the treatment of schizophrenia we expect top-line data readout for both mono-therapy studies (401 and 404) simultaneously in 2Q19.",,,,1101922580901056512,https://twitter.com/semodough/status/1101922580901056512
2019-02-21 11:41:20,semodough,,1,0,1,"JP $ITCI acknowledge CNS trials can carry above-average risk,see 2019 shaping up to be a transformative year for ITCI with potential for substantial additional value creation as trials read out for lumateperone’s label expansion opportunities for which see little credit in stock",,,,1098548219716534273,https://twitter.com/semodough/status/1098548219716534273
2019-02-13 14:56:15,semodough,,1,0,7,"RBC $ITCI favorable FDA panel $JNJ esketamine provides additional evidence of regulatory comfort in viewing psychiatric drugs favorably despite mixed efficacy data.indirect but positive read-throughs for potential for ITCI lumateperone to gain approval in schizophrenia 9/27 PDUFA",,,,1095698169462251522,https://twitter.com/semodough/status/1095698169462251522
2019-02-12 13:01:38,JalrOrg,,0,0,0,"Clinical Pharmacology of Miami Paid Clinical Trial Healthy Volunteers Miami, FL An Open-label, Parallel Group Study to Determine the Pharmacokinetics of a Lumateperone Orally Disintegrating Tablet (ODT) Following Sublingual (SL) Administration More here http://ow.ly/ZIfj30nExOE",,,,1095306937976143872,https://twitter.com/JalrOrg/status/1095306937976143872
2019-01-25 19:26:45,TrialBulletin,,0,0,0,"ITI-007 (Lumateperone Tosylate) for Schizophrenia: Status: Not yet recruiting, Condition Summary: Schizophrenia ",,,,1088880874374995968,https://twitter.com/TrialBulletin/status/1088880874374995968
2019-01-25 14:29:28,CureHuntr,,0,0,0,"#clinicaltrial ITI-007 (Lumateperone Tosylate) for Schizophrenia http://bit.ly/2FNXiLh",,,#clinicaltrial,1088806062222962689,https://twitter.com/CureHuntr/status/1088806062222962689
2018-12-22 23:20:18,medicalnewser,,0,0,0,"Intra-Cellular Therapies Announces FDA Acceptance of New Drug Application for Lumateperone for the Treatment of Schizophrenia...",,,,1076618462724849665,https://twitter.com/medicalnewser/status/1076618462724849665
2018-12-17 20:00:41,PsychiatryAdv,,0,0,0,"Intra-Cellular Therapies announced that the @US_FDA has accepted for review the New Drug Application for lumateperone (ITI-007) for the treatment of #schizophrenia.",,@US_FDA,#schizophrenia,1074756287009841153,https://twitter.com/PsychiatryAdv/status/1074756287009841153
2018-12-13 12:54:49,SchizophrenNews,,0,0,0,"FDA to Review Lumateperone for Treatment of Schizophrenia #Schizophrenia",,,#Schizophrenia,1073199560741265415,https://twitter.com/SchizophrenNews/status/1073199560741265415
2018-12-12 22:06:46,investpro2000,,0,1,1,"$itci Intra-Cellular Therapies Announces Favorable Results From Long-Term Open-Label Safety Switching Study With Lumateperone in Patients with Schizophrenia at the 57th Annual Meeting of the American College of Neuropsychopharmacology ",,,,1072976078434635782,https://twitter.com/investpro2000/status/1072976078434635782
2018-12-12 06:24:08,ACInvestorBlog,,0,1,4,"$ITCI Announces Favorable Results From Long-Term Open-Label Safety Switching Study With Lumateperone in Patients https://globenewswire.com/news-release/2018/12/11/1665575/0/en/Intra-Cellular-Therapies-Announces-Favorable-Results-From-Long-Term-Open-Label-Safety-Switching-Study-With-Lumateperone-in-Patients-with-Schizophrenia-at-the-57th-Annual-Meeting-of.html",,,,1072738858226331648,https://twitter.com/ACInvestorBlog/status/1072738858226331648
2018-12-11 22:50:20,NordEkoNorge,,0,0,0,"Intra-Cellular Therapies Announces Favorable Results From Long-Term Open-Label Safety Switching Study With Lumateperone in Patients with Schizophrenia at the 57th Annual Meeting of the American College of Neuropsychopharmacology...",,,,1072624653624098816,https://twitter.com/NordEkoNorge/status/1072624653624098816
2018-12-11 18:30:38,bs2537,,0,2,5,"Great news for schizophrenia patients and Intracellular therapies, $ITCI investors. FDA finally accepts NDA for lumateperone. There is a great unmet need for safer drugs in this space.",,,,1072559296402128896,https://twitter.com/bs2537/status/1072559296402128896
2018-12-11 14:08:36,stewdomer,,0,0,0,"Intra-Cellular Therapies Announces FDA Acceptance Of New Drug Application For Lumateperone For The Treatment Of Schizophrenia $ITCI...yooglee chart and thin trader",,,,1072493356037619712,https://twitter.com/stewdomer/status/1072493356037619712
2018-12-11 14:04:51,Briefingcom,,0,1,1,"$ITCI: Intra-Cellular Therapies announces FDA has accepted for approval NDA regarding lumateperone http://bit.ly/2Bc6mow",,,,1072492410184318976,https://twitter.com/Briefingcom/status/1072492410184318976
2018-12-11 13:46:53,HottestStockNow,,0,0,0,"FDA to Review $ITCI 's New Drug Application for Lumateperone for the Treatment of Schizophrenia http://crweworld.com/symbol/ITCI",,,,1072487889509015552,https://twitter.com/HottestStockNow/status/1072487889509015552
2018-12-11 12:12:43,Trade_The_News,,0,0,0,"$ITCI FDA accepts New Drug Application for Lumateperone for Treatment of Schizophrenia (Intra-Cellular Therapies, Inc.) (More at https://www.tradethenews.com/?twtId=5100)",,,,1072464194149191680,https://twitter.com/Trade_The_News/status/1072464194149191680
2018-12-11 12:05:11,CrweWorld,,0,0,0,"Intra-Cellular Therapies Announces FDA Acceptance of New Drug Application for Lumateperone for the Treatment of Schi ",,,,1072462295522033664,https://twitter.com/CrweWorld/status/1072462295522033664
2018-12-11 12:01:35,BioStocks,,0,2,2,"$ITCI FDA Accepts NDA for Lumateperone for the Treatment of Schizophrenia. PDUFA 09/27/19",,,,1072461388839297027,https://twitter.com/BioStocks/status/1072461388839297027
2018-12-09 14:00:19,Dra_TeraizaMesa,,0,2,1,"Dopamine D 2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia | Neuropsychopharmacology https://www.nature.com/articles/s41386-018-0251-1",,,,1071766494231650305,https://twitter.com/Dra_TeraizaMesa/status/1071766494231650305
2018-12-09 14:00:12,Dra_TeraizaMesa,,0,0,0,"Dopamine D 2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia | Neuropsychopharmacology https://www.nature.com/articles/s41386-018-0251-1",,,,1071766464858914819,https://twitter.com/Dra_TeraizaMesa/status/1071766464858914819
2018-12-05 01:46:31,RoccoLefkowitz,,0,0,2,"Added 1000 $ITCI at 14.2 for total 5000 shares cost basis 15.78. Lumateperone NDA acceptance? Tick ... tick ... tick",,,,1070132277722648576,https://twitter.com/RoccoLefkowitz/status/1070132277722648576
2018-11-27 16:42:17,zbiotech,,0,1,2,"$ITCI FDA decision on lumateperone NDA acceptance should happen soon",,,,1067458602120724490,https://twitter.com/zbiotech/status/1067458602120724490
2018-11-07 16:23:57,semodough,,0,0,1,"JP $ITCI Not Depressed About These Updates; Bipolar Phase IIIs Now Coming Together, Setting Up a Potential Big 2Q19 analyze two phase III lumateperone monotherapy bipolar depression trials simultaneously makes a lot of sense, given high pbo responses typically observedpsychiatry",,,,1060206227899236357,https://twitter.com/semodough/status/1060206227899236357
2018-10-26 19:44:07,aghoury79,,0,0,0,"Dopamine D2 receptor occupancy of lumateperone (ITI-007): a Positron Emission Tomography Study in patients with schizophrenia https://go.nature.com/2Jhckbz",,,,1055907949120548864,https://twitter.com/aghoury79/status/1055907949120548864
2018-10-26 07:03:39,Lecomprime,,0,0,0,"What's In The Pipeline ? 5. La Lumateperone, un Antipsychotique Sans Effets Secondaires ? ",,,,1055716571140763648,https://twitter.com/Lecomprime/status/1055716571140763648
2018-10-19 20:00:58,PsychiatryAdv,,1,0,1,"Intra-Cellular Therapies has submitted its New Drug Application for #lumateperone, a once-daily, oral investigational medicine for the treatment of #schizophrenia.",,,#lumateperone #schizophrenia,1053375472841773056,https://twitter.com/PsychiatryAdv/status/1053375472841773056
2018-10-18 04:24:58,aakershita,MarketCurrents,0,0,0,"Big things coming for lumateperone (ITI-007) ",,,,1052777533635059712,https://twitter.com/aakershita/status/1052777533635059712
2018-10-03 16:45:15,medicalnewser,,0,0,0,"Intra-Cellular Therapies Completes Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia...",,,,1047528015754944512,https://twitter.com/medicalnewser/status/1047528015754944512
2018-10-03 16:01:57,PsychiatryAdv,,0,0,0,"Intra-Cellular Therapies has submitted its New Drug Application for lumateperone, a once-daily, oral investigational medicine for the treatment of #schizophrenia. https://bit.ly/2OrKbnb",,,#schizophrenia,1047517116713369600,https://twitter.com/PsychiatryAdv/status/1047517116713369600
2018-10-01 17:01:16,PlexusVentures,,0,0,0,"#IntraCellularTherapies: Betting On A Safer Drug https://seekingalpha.com/article/4208573-intra-cellular-therapies-betting-safer-drug?source=tweet @SeekingAlpha $ITCI #ITCI #CNS #schizophrenia #Lumateperone #bipolardepression #agitation #dementia #PDEinhibitors #heartdisease",,@SeekingAlpha,#IntraCellularTherapies #ITCI #CNS #schizophrenia #Lumateperone #bipolardepression #agitation #dementia #PDEinhibitors #heartdisease,1046807268786941952,https://twitter.com/PlexusVentures/status/1046807268786941952
2018-09-29 02:10:11,crusadernz,,0,4,2,"Biotech updates 09/28 $REGN $SNY cemiplimab approval $INSM Arikayce FDA approval $ITCI completes lumateperone NDA filing $AKTX pipeline update",,,,1045858247146532864,https://twitter.com/crusadernz/status/1045858247146532864
2018-09-28 18:55:59,MaisaCorp,,0,0,0,"$ITCI Completes Submission Of NDA For Lumateperone",,,,1045748974089633792,https://twitter.com/MaisaCorp/status/1045748974089633792
2018-09-28 18:45:05,semodough,,0,0,1,"JP $ITCI Bigger picture, while we acknowledge CNS trials can carry above- average risk, we see potential for substantial additional value creation as multiple phase IIIs read out for lumateperone’s label expansion opportunities.",,,,1045746233640452097,https://twitter.com/semodough/status/1045746233640452097
2018-09-28 12:10:54,financialbuzz,,0,0,0,"Intra-Cellular Therapies Completes Submission of New Drug Application for Lumateperone for Treatment of Schizoph.. http://financialbuzz.com/intra-cellular-therapies-completes-submission-of-new-drug-application-for-lumateperone-for-treatment-of-schizophrenia-1195652",,,,1045647034034704386,https://twitter.com/financialbuzz/status/1045647034034704386
2018-09-28 11:29:34,MarketCurrents,,0,0,0,"Intra-Cellular Therapies completes NDA submission for Lumateperone https://seekingalpha.com/news/3393657-intra-cellular-therapies-completes-nda-submission-lumateperone?source=feed_f #premarket $ITCI",,,#premarket,1045636632060149761,https://twitter.com/MarketCurrents/status/1045636632060149761
2018-09-28 11:05:18,odibro,,1,2,1,"$ITCI Completes Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia https://finance.yahoo.com/news/intra-cellular-therapies-completes-submission-110000082.html",,,,1045630523010371584,https://twitter.com/odibro/status/1045630523010371584
2018-09-28 11:05:05,CrweWorld,,0,0,0,"Intra-Cellular Therapies Completes Submission of New Drug Application for Lumateperone for Treatment of Schizophreni ",,,,1045630471701389312,https://twitter.com/CrweWorld/status/1045630471701389312
2018-09-28 11:04:27,BioStocks,,0,0,1,"$ITCI Completes Submission of NDA for Lumateperone for Treatment of Schizophrenia",,,,1045630309817966592,https://twitter.com/BioStocks/status/1045630309817966592
2018-09-28 11:03:07,NewsFromSPI,,0,0,0,"Intra-Cellular Therapies Completes Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia http://ow.ly/Lf3a101h1BD",,,,1045629974676418560,https://twitter.com/NewsFromSPI/status/1045629974676418560
2018-09-22 18:35:43,semodough,,1,1,3,"RBC $ITCI very much like reward/risk ~$1.1B valuation,considering &gt;$1.5B opportunity see for lumateperone across schizophrenia, bipolar,dementia indications &amp;limited credit they get for indications/programs beyond schizophrenia, year-end we believe could see shares get into $40s",,,,1043569550019780608,https://twitter.com/semodough/status/1043569550019780608
2018-09-10 22:25:52,CashRocket,,1,0,2,"Therefore, I am long Jan '19 30 calls. $ITCI remains on track to complete its NDA (lumateperone in schizophrenia) any day now. Also awaiting top-line Phase III data (lumateperone in bipolar depression). A promising late-stage asset in the neuropsychiatry space, great risk-reward.",,,,1039278810829443072,https://twitter.com/CashRocket/status/1039278810829443072
2018-09-06 11:34:06,OMENSOL,,0,0,0,"Drug analysis: Lumateperone #Drug Overview Lumateperone is a novel, orally available antipsychotic being developed by Intra-Cellular Therapies for several neuropsychiatric disorders. Lumateperone acts as a serotonin 5-HT2A receptor antagonist, a modulato…",,,#Drug,1037665238177472513,https://twitter.com/OMENSOL/status/1037665238177472513
2018-08-29 10:11:04,OMENSOL,,0,0,0,"Drug analysis: Lumateperone ~ "" #Drug Overview #Lumateperone is a novel, orally available antipsychotic being developed by Intra-Cellular Therapies for several neuropsychiatric disorders. Lumateperone acts as a serotonin 5-HT2A receptor antagonist, a modu…",,,#Drug #Lumateperone,1034745240324911104,https://twitter.com/OMENSOL/status/1034745240324911104
2018-08-03 11:38:15,semodough,,0,0,3,"Laden $ITCI Lumateperone NDA Nears Completion; Bipolar Phase 3 Data 2H18; Buy and $33 PT",,,,1025345097750204416,https://twitter.com/semodough/status/1025345097750204416
2018-07-23 18:29:21,Cortellis,,0,0,1,"ITI-007 (Lumateperone) phase 2 trial results show it is safe and well tolerated up to a dose of 30 mg in healthy elderly subjects and at 9 mg dose in elderly patients with dementia. Live from #AAIC18",,,#AAIC18,1021462285641035782,https://twitter.com/Cortellis/status/1021462285641035782
2018-06-23 19:07:17,RoccoLefkowitz,,1,0,0,"I have 2000 shares of $ITCI cost basis 16.19 and think the position has potential to become very profitable in H2 2018 if FDA accepts lumateperone NDA and company reports encouraging results of other ongoing trials.",,,,1010600197540536320,https://twitter.com/RoccoLefkowitz/status/1010600197540536320
2018-06-23 19:04:53,RoccoLefkowitz,,1,0,0,"The next event people should be looking at closely for lumateperone for schizophrenia isn't the PDUFA, but rather FDA acceptance of the NDA (whose rolling submission is not yet completed). It seems the major overhang is the initial RTF delivered to $ALKS for a similar submission.",,,,1010599592369549314,https://twitter.com/RoccoLefkowitz/status/1010599592369549314
2018-06-16 18:50:16,medicalnewser,,0,0,0,"Intra-Cellular Therapies Initiates Rolling Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia - ...",,,,1008059196888240128,https://twitter.com/medicalnewser/status/1008059196888240128
2018-06-07 00:30:23,crusadernz,,0,5,6,"Biotech updates 06/06: $AXON +160% license deal $ITCI lumateperone NDA filing $ZYME $VKTX $MRTX offerings $GSK Mepolizumab Adcom 7/25 + Pipeline updates for $ALKS $CLRB $NITE $OPK $PTI $SCYX",,,,1004520914925391874,https://twitter.com/crusadernz/status/1004520914925391874
2018-06-06 21:14:15,MaisaCorp,,0,1,0,"$ITCI has begun a rolling submission for the new drug application for its lumateperone drug candidate, with plans to complete the application by mid-year",,,,1004471552988020736,https://twitter.com/MaisaCorp/status/1004471552988020736
2018-06-06 13:50:52,TINMobileNews,,0,0,0,"Intra-Cellular initiates rolling submission of NDA for lumateperone (The Fly) http://dlvr.it/QWNTdt",,,,1004359973827047424,https://twitter.com/TINMobileNews/status/1004359973827047424
2018-06-06 13:04:10,Briefingcom,,0,0,0,"$ITCI: Intra-Cellular Therapies initiates a rolling submission of its NDA w/ the FDA for lumateperone for the... http://bit.ly/2sJMDZb",,,,1004348219906613248,https://twitter.com/Briefingcom/status/1004348219906613248
2018-06-06 13:03:09,SchizophrenNews,,0,0,1,"Intra-Cellular Therapies (ITCI) Initiates Rolling Submission of NDA for Lumateperone for.. #schizophrenia #bhive http://dld.bz/gQSPt",,,#schizophrenia #bhive,1004347967178969090,https://twitter.com/SchizophrenNews/status/1004347967178969090
2018-06-06 12:10:24,financialbuzz,,0,0,0,"Intra-Cellular Therapies Initiates Rolling Submission of New Drug Application for Lumateperone for Treatment of .. http://financialbuzz.com/intra-cellular-therapies-initiates-rolling-submission-of-new-drug-application-for-lumateperone-for-treatment-of-schizophrenia-1111030",,,,1004334690612867072,https://twitter.com/financialbuzz/status/1004334690612867072
2018-06-06 11:40:46,MarketCurrents,,0,0,0,"Intra-Cellular initiates rolling NDA submission for schizophrenia med lumateperone https://seekingalpha.com/news/3361965-intra-cellular-initiates-rolling-nda-submission-schizophrenia-med-lumateperone?source=feed_f #premarket $ITCI",,,#premarket,1004327231592624133,https://twitter.com/MarketCurrents/status/1004327231592624133
2018-06-06 11:16:05,StockGuruDotCom,,0,0,0,"Intra-Cellular Therapies Initiates Rolling Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia https://stockguru.com/2018/06/06/intra-cellular-therapies-initiates-rolling-submission-of-new-drug-application-for-lumateperone-for-treatment-of-schizophrenia/",,,,1004321021925773313,https://twitter.com/StockGuruDotCom/status/1004321021925773313
2018-06-06 11:05:53,CrweWorld,,0,0,0,"Intra-Cellular Therapies Initiates Rolling Submission of New Drug Application for Lumateperone for Treatment of Schi http://crweworld.com/article/news-provided-by-globenewswire/315334/intra-cellular-therapies-initiates-rolling-submission-of-new-drug-application-for-lumateperone-for-treatment-of-schizophrenia",,,,1004318452583034880,https://twitter.com/CrweWorld/status/1004318452583034880
2018-06-06 11:05:18,DonnaYoungDC,,0,0,0,"$ITCI Initiates Rolling Submission of NDA to #FDA for #Lumateperone for Treatment of #Schizophrenia https://finance.yahoo.com/news/intra-cellular-therapies-initiates-rolling-110000513.html #pharma #biotech",,,#FDA #Lumateperone #Schizophrenia #pharma #biotech,1004318306319454209,https://twitter.com/DonnaYoungDC/status/1004318306319454209
2018-06-06 11:04:58,stocknewsdotcom,,0,0,0,"$ITCI Initiates a rolling submission of its NDA w/ the FDA for lumateperone for the treatment of schizophrenia; co… https://stocknews.com/news/itci-initiates-a-rolling-submission-of-its-nda-w-the-fda/",,,,1004318223133757440,https://twitter.com/stocknewsdotcom/status/1004318223133757440
2018-06-06 11:04:28,odibro,,0,1,2,"$ITCI Initiates Rolling Submission of New Drug Application for Lumateperone for Treatment of Schizophrenia ",,,,1004318098135093250,https://twitter.com/odibro/status/1004318098135093250
2018-06-06 11:03:18,NewsFromSPI,,0,0,0,"Intra-Cellular Therapies Initiates Rolling Submission of New Drug Application for Lumateperone for Treatment of... http://ow.ly/fWrM1016M2d",,,,1004317805716664321,https://twitter.com/NewsFromSPI/status/1004317805716664321
2018-06-06 11:01:40,BioStocks,,0,0,0,"$ITCI Initiates Rolling NDA Submission for Lumateperone for Treatment of Schizophrenia",,,,1004317392321667072,https://twitter.com/BioStocks/status/1004317392321667072
2018-05-31 12:09:44,financialbuzz,,0,0,0,"Intra-Cellular Therapies Presents Data on Symptom Improvement by Lumateperone on Negative Symptoms, Depression, .. http://financialbuzz.com/intra-cellular-therapies-presents-data-on-symptom-improvement-by-lumateperone-on-negative-symptoms-depression-and-social-function-in-patients-with-schizophrenia-at-the-american-society-of-clinical-psy-1105691",,,,1002160194468507648,https://twitter.com/financialbuzz/status/1002160194468507648
2018-05-31 12:04:37,NewsFromSPI,,0,0,0,"Intra-Cellular Therapies Presents Data on Symptom Improvement by Lumateperone on Negative Symptoms, Depression,... ",,,,1002158908327198720,https://twitter.com/NewsFromSPI/status/1002158908327198720
2018-05-29 14:20:05,pharminews,,0,0,0,"Intra-Cellular Therapies Announces Presentations on Lumateperone at the… https://goo.gl/fb/LG2A5i #news #pharma",,,#news #pharma,1001468224280678401,https://twitter.com/pharminews/status/1001468224280678401
2018-05-29 12:09:50,financialbuzz,,0,0,0,"Intra-Cellular Therapies Announces Presentations on Lumateperone at the American Society of Clinical Psychopharm.. http://financialbuzz.com/intra-cellular-therapies-announces-presentations-on-lumateperone-at-the-american-society-of-clinical-psychopharmacology-ascp-annual-meeting-1102876",,,,1001435444582600704,https://twitter.com/financialbuzz/status/1001435444582600704
2018-05-29 12:06:47,NewsFromSPI,,0,0,0,"Intra-Cellular Therapies Announces Presentations on Lumateperone at the American Society of Clinical... http://ow.ly/pZla10161z5",,,,1001434676060356608,https://twitter.com/NewsFromSPI/status/1001434676060356608
2018-05-29 12:05:09,CrweWorld,,0,0,0,"Intra-Cellular Therapies Announces Presentations on Lumateperone at the American Society of Clinical Psychopharmacol http://crweworld.com/article/news-provided-by-globenewswire/309164/intra-cellular-therapies-announces-presentations-on-lumateperone-at-the-american-society-of-clinical-psychopharmacology-ascp-annual-meeting",,,,1001434268332048384,https://twitter.com/CrweWorld/status/1001434268332048384
2018-05-16 10:09:21,financialbuzz,,0,0,0,"Lumateperone (Intra-Cellular Therapies) Drug Overview: A Serotonin 5-HT2A Receptor Antagonist, a Modulator of th.. http://financialbuzz.com/lumateperone-intra-cellular-therapies-drug-overview-a-serotonin-5-ht2a-receptor-antagonist-a-modulator-of-the-dopaminergic-and-glutamatergic-systems-and-a-serotonin-reuptake-inhibitor-researchandmarkets-com-1092569",,,,996694082876395521,https://twitter.com/financialbuzz/status/996694082876395521
2018-05-16 09:04:29,PharmaMKTnet,,0,0,0,"Lumateperone (Intra-Cellular Therapies) Drug Overview: A Serotonin 5-HT2A Receptor Antagonist, a Modulator of the Dopaminergic and Glutamatergic Systems, and a Serotonin Reuptake Inhibitor - http://ResearchAndMarkets.com https://ift.tt/2KuS05Z via BusinessWire",,,,996677759287156736,https://twitter.com/PharmaMKTnet/status/996677759287156736
2018-05-16 09:01:05,Market_Screener,,0,0,0,"Lumateperone (Intra-Cellular Therapies) Drug Overview: A Serotonin 5-HT2A Receptor Antagonist, a Modulator of the Dopaminergic and Glutamatergic Systems, and a Serotonin Reuptake Inhibitor - http://ResearchAndMarkets.com http://www.4-traders.com/news/Lumateperone-Intra-Cellular-Therapies-Drug-Overview-A-Serotonin-5-HT2A-Receptor-Antagonist-a-Mod--26594954/",,,,996676900310470656,https://twitter.com/Market_Screener/status/996676900310470656
2018-05-11 19:52:33,PharmaMKTnet,,0,0,0,"Lumateperone (Intra-Cellular Therapies) Drug Overview: A Serotonin 5-HT2A Receptor Antagonist, a Modulator of the Dopaminergic and Glutamatergic Systems, and a Serotonin Reuptake Inhibitor - http://ResearchAndMarkets.com https://ift.tt/2IwV6Jf via BusinessWire",,,,995028907899355136,https://twitter.com/PharmaMKTnet/status/995028907899355136
2018-05-06 20:39:06,HottestStockNow,,0,0,0,"$ITCI to reveal key findings from lumateperone clinical development programs in schizophrenia &amp; depressive disorders http://crweworld.com/article/news-provided-by-globenewswire/289407/intra-cellular-therapies-announces-presentations-on-lumateperone-at-two-upcoming-medical-conferences",,,,993228686848659457,https://twitter.com/HottestStockNow/status/993228686848659457
2018-05-04 13:03:19,SchizophrenNews,,0,0,0,"Intra-Cellular Therapies Announces Presentations on Lumateperone at Two Upcoming Medical.. #schizophrenia #bhive http://dld.bz/gNap6",,,#schizophrenia #bhive,992389207967567872,https://twitter.com/SchizophrenNews/status/992389207967567872
2018-05-04 12:22:00,StockGuruDotCom,,0,0,0,"Intra-Cellular Therapies Announces Presentations on Lumateperone at Two Upcoming Medical Conferences https://stockguru.com/2018/05/04/intra-cellular-therapies-announces-presentations-on-lumateperone-at-two-upcoming-medical-conferences/",,,,992378810300428290,https://twitter.com/StockGuruDotCom/status/992378810300428290
2018-05-04 12:09:35,financialbuzz,,0,0,0,"Intra-Cellular Therapies Announces Presentations on Lumateperone at Two Upcoming Medical Conferences http://financialbuzz.com/intra-cellular-therapies-announces-presentations-on-lumateperone-at-two-upcoming-medical-conferences-1080870",,,,992375684839260161,https://twitter.com/financialbuzz/status/992375684839260161
2018-05-04 12:02:25,NewsFromSPI,,0,0,0,"Intra-Cellular Therapies Announces Presentations on Lumateperone at Two Upcoming Medical Conferences http://ow.ly/8uxM1013QbM",,,,992373881703976960,https://twitter.com/NewsFromSPI/status/992373881703976960
2018-05-04 12:01:17,Market_Screener,,0,0,0,"Intra-Cellular Therapies Announces Presentations on Lumateperone at Two Upcoming Medical Conferences ",,,,992373598282186752,https://twitter.com/Market_Screener/status/992373598282186752
2018-04-14 21:18:33,adnewstoday,,0,0,0,"We’ve updated one of our resource pages with new information. Take a look: Lumateperone (ITI-007) ",,,,985266080691228674,https://twitter.com/adnewstoday/status/985266080691228674
2018-04-14 21:16:34,adnewstoday,,0,0,0,"New Post: Lumateperone (ITI-007) https://buff.ly/2EK5QOs",,,,985265580725948416,https://twitter.com/adnewstoday/status/985265580725948416
2018-04-03 15:09:19,jfais20,,0,1,1,"$ITCI sold off on news related to RTF for $ALKS, Canaccord says pullback is buying opportunity ahead of midyear regulatory filing for lumateperone for depression (has more conventional design), $31 price target",,,,981186890836701185,https://twitter.com/jfais20/status/981186890836701185
2018-04-02 19:54:47,RJ248842,BIOBETTER,0,0,0,"Incorrect. $ITCI has two lumateperone trials that achieved statistical significance on a prospectively defined efficacy endpoint. One of the two trials was P2; however, the N was very large (335). Another trial, in P3, failed to achieve significance.",,,,980896345987977216,https://twitter.com/RJ248842/status/980896345987977216
2018-04-02 14:34:01,RJ248842,adamfeuerstein,0,0,0,"There’s an error in your article. $ITCI seeks approval for lumateperone based on two trials, not one, including trial #ITI-007-005 (N=335), that achieved their prospective efficacy endpoint. See p. 10 of http://ir.intracellulartherapies.com/static-files/e3ede930-b7d2-48f1-b84c-cfb5f4bed62f.",,,,980815619598766080,https://twitter.com/RJ248842/status/980815619598766080
2018-04-02 12:45:19,RJ248842,adamfeuerstein,0,0,0,"Sure, on $ITCI lumateperone v. $ALKS 5461. If you look at precedent, you’ll find two large, randomized, controlled trials are, “substantial evidence,” of safety and efficacy, even if other such studies are done and fail.",,,,980788264591417346,https://twitter.com/RJ248842/status/980788264591417346
2018-04-02 12:10:45,donvanvliet3,vigkap,1,2,5,"The analogy to lumateperone is superficial at best; the successful phase II trial included 355 patients and was well controlled, with an active commparator and placebo. Drug has fast track designation &amp; $ITCI reported a successful pre-NDA meeting with plans to submit rolling NDA.",,,,980779566435307521,https://twitter.com/donvanvliet3/status/980779566435307521
2018-04-02 11:56:27,RJ248842,adamfeuerstein,1,0,3,"Not comparable. $ITCI has supported its lumateperone NDA with two large, randomized, placebo controlled studies that both achieved statistical significance on prospectively defined endpoints w strong safety profile.$ALKS 5461 had only one such study.",,,,980775968431333376,https://twitter.com/RJ248842/status/980775968431333376
2018-03-18 23:45:07,NeuralCell,,0,0,0,"Intra-Cellular Therapies Announces Positive Pre-NDA Meeting w/ FDA for Lumateperone for the Treatment of Schizophrenia ",,,,975518492874199040,https://twitter.com/NeuralCell/status/975518492874199040
2018-03-15 11:53:11,Market_Screener,,0,0,0,"Intra-Cellular Therapies Inc : Wired News  FDA Approved Intra-Cellulars Rolling NDA Submission for Lumateperone for Schizophrenia ",,,,974252165287088128,https://twitter.com/Market_Screener/status/974252165287088128
2018-03-14 17:00:25,pharmacychecker,,0,0,0,"The FDA and Intra-Cellular Therapies have reached an agreement on the proposed content and timing of a rolling new drug application submission for lumateperone, which is indicated to treat patients with schizophrenia ",,,,973967093124272132,https://twitter.com/pharmacychecker/status/973967093124272132
2018-03-14 16:30:01,SciMts,,0,1,1,"Characterization of the interaction of the atypical #antipsychotic #Lumateperone with the #dopamine D2 receptors. Learn more here @SciMts http://dld.bz/gGeHd",,@SciMts,#antipsychotic #Lumateperone #dopamine,973959444458504193,https://twitter.com/SciMts/status/973959444458504193
2018-03-14 10:49:55,semodough,,0,0,1,"Laden $ITCI Positive Lumateperone Pre-NDA Meeting: Mid-18 Filing On-track; Buy and $33 PT",,,,973873856065822720,https://twitter.com/semodough/status/973873856065822720
2018-03-13 13:38:21,Briefingcom,,0,0,0,"$ITCI: Intra-Cellular Therapies had a 'positive pre-NDA meeting with the FDA regarding lumateperone for the... http://bit.ly/2FDRH6B",,,,973553856591228929,https://twitter.com/Briefingcom/status/973553856591228929
2018-03-13 12:50:18,businesstuknews,,0,0,0,"FDA on board with Intra-Cellular's rolling NDA for lumateperone for schizophrenia http://forexparrot.com/fda-on-board-with-intra-cellulars-rolling-nda-for-lumateperone-for-schizophrenia/",,,,973541764941471745,https://twitter.com/businesstuknews/status/973541764941471745
2018-03-13 12:46:06,MarketCurrents,,0,0,0,"FDA on board with Intra-Cellular's rolling NDA for lumateperone for schizophrenia https://seekingalpha.com/news/3338682-fda-board-intra-cellulars-rolling-nda-lumateperone-schizophrenia?source=feed_f #premarket $ITCI",,,#premarket,973540704583434240,https://twitter.com/MarketCurrents/status/973540704583434240
2018-03-13 12:14:13,STOCKWINNERScom,,0,0,0,"Intra-Cellular announces 'positive' pre-NDA meeting with FDA for lumateperone Intra-Cellular Therapies (ITCI)... https://fb.me/9pQPz1EjO",,,,973532682595467265,https://twitter.com/STOCKWINNERScom/status/973532682595467265
2018-03-13 12:10:01,financialbuzz,,0,0,0,"Intra-Cellular Therapies Announces Positive Pre-NDA Meeting with FDA for Lumateperone for the Treatment of Schiz.. http://financialbuzz.com/intra-cellular-therapies-announces-positive-pre-nda-meeting-with-fda-for-lumateperone-for-the-treatment-of-schizophrenia-1030560",,,,973531624217325570,https://twitter.com/financialbuzz/status/973531624217325570
2018-03-13 11:51:39,StockGuruDotCom,,0,0,0,"Intra-Cellular Therapies Announces Positive Pre-NDA Meeting with FDA for Lumateperone for the Treatment of Schizophrenia ",,,,973527004900360195,https://twitter.com/StockGuruDotCom/status/973527004900360195
2018-03-13 11:39:34,stocknewsdotcom,,0,0,0,"$ITCI Company had a 'positive pre-NDA meeting with the FDA regarding lumateperone for the treatment of schizophre… https://stocknews.com/news/itci-company-had-a-positive-pre-nda-meeting-with-the-fda-regarding/",,,,973523960796254208,https://twitter.com/stocknewsdotcom/status/973523960796254208
2018-03-13 11:32:34,odibro,,0,2,3,"$ITCI Announces Positive Pre-NDA Meeting with FDA for Lumateperone for the Treatment of Schizophrenia https://globenewswire.com/news-release/2018/03/13/1421156/0/en/Intra-Cellular-Therapies-Announces-Positive-Pre-NDA-Meeting-with-FDA-for-Lumateperone-for-the-Treatment-of-Schizophrenia.html",,,,973522198873956352,https://twitter.com/odibro/status/973522198873956352
2018-03-13 11:32:08,BioStocks,,0,3,6,"$ITCI Announces Positive Pre-NDA Meeting with FDA for Lumateperone for the Treatment of Schizophrenia. Agreement with FDA on the proposed content and timing of a rolling NDA submission.",,,,973522091306713088,https://twitter.com/BioStocks/status/973522091306713088
2018-03-13 11:31:07,NewsFromSPI,,0,0,0,"Intra-Cellular Therapies Announces Positive Pre-NDA Meeting with FDA for Lumateperone for the Treatment of... http://ow.ly/DA6V100Z8PT",,,,973521837475975168,https://twitter.com/NewsFromSPI/status/973521837475975168
2018-03-05 19:44:40,jfais20,,1,0,2,"$ITCI SunTrust boosts price target to $29, focused on pre-NDA meeting with FDA for lumateperone for schizophrenia this quarter, includes bipolar depression in his model with P2 results coming 2H 18",,,,970746937300353024,https://twitter.com/jfais20/status/970746937300353024
2018-03-02 11:38:40,semodough,,1,0,3,"Laden $ITCI Lumateperone NDA Filing Mid-2018; 4Q17 Results; Buy Rating and $33 PT",,,,969537468520378368,https://twitter.com/semodough/status/969537468520378368
2018-03-01 12:13:15,BioStocks,,0,1,3,"$ITCI to submit NDA for Lumateperone for the treatment of schizophrenia by mid-2018. ",,,,969183786415083521,https://twitter.com/BioStocks/status/969183786415083521
2018-02-12 19:46:17,Slingshot_Invst,,0,0,2,"15 minutes until our call w/ Expert on $ITCI 's Lumateperone for depression &amp; schizophrenia. Join to listen live or to recording/transcript later --&gt;",,,,963137199440097286,https://twitter.com/Slingshot_Invst/status/963137199440097286
2018-01-17 22:28:52,Wondermoon__,,0,0,2,"Just got sucked into a google rabbit hole about a drug named lumateperone that hasn’t been released yet but doesn’t have all the negative side effects??!?",,,,953756031095631872,https://twitter.com/Wondermoon__/status/953756031095631872
2017-12-15 10:34:03,AnalystWire,,0,0,0,"Canaccord Genuity Starts Intra-Cellular Therapies $ITCI at Buy, 'Lumateperone on track as ITCI ... ",,,,941617343159029760,https://twitter.com/AnalystWire/status/941617343159029760
2017-12-07 20:08:41,HottestStockNow,,0,0,0,"$ITCI Reveals Findings on Lumateperone, ITI-214 and ITI-333 in patients with central nervous system disorders ",,,,938862848876449792,https://twitter.com/HottestStockNow/status/938862848876449792
2017-12-07 16:05:38,SchizophrenNews,,0,0,0,"Intra-Cellular Therapies Presents Data on Lumateperone, ITI-214 and ITI-333 at the 56th .. #schizophrenia #bhive http://dld.bz/gxEst",,,#schizophrenia #bhive,938801683307679747,https://twitter.com/SchizophrenNews/status/938801683307679747
2017-12-07 16:01:47,ImperialVlNews,,0,0,0,"Intra-Cellular Therapies Presents Data on Lumateperone, ITI-214 and ITI-333 at the 56th Annual ... http://zpr.io/n7GXQ",,,,938800717044813826,https://twitter.com/ImperialVlNews/status/938800717044813826
2017-12-07 16:01:10,DesertCtrNews,,0,0,0,"Intra-Cellular Therapies Presents Data on Lumateperone, ITI-214 and ITI-333 at the 56th Annual ... http://zpr.io/n7GXQ",,,,938800560177926144,https://twitter.com/DesertCtrNews/status/938800560177926144
2017-12-07 15:59:28,CoachellaVlNews,,0,0,0,"Intra-Cellular Therapies Presents Data on Lumateperone, ITI-214 and ITI-333 at the 56th Annual ... http://zpr.io/n7GXQ",,,,938800133445181440,https://twitter.com/CoachellaVlNews/status/938800133445181440
2017-12-07 14:02:56,financialbuzz,,0,0,0,"Intra-Cellular Therapies Presents Data on Lumateperone, ITI-214 and ITI-333 at the 56th Annual Meeting of the Am.. http://financialbuzz.com/intra-cellular-therapies-presents-data-on-lumateperone-iti-and-iti-at-the-th-annual-meeting-of-the-american-college-of-neuropsychopharmacology-952498",,,,938770806145826821,https://twitter.com/financialbuzz/status/938770806145826821
2017-12-07 13:05:48,stockboardinc,,0,0,0,"$ITCI Intra-Cellular Therapies Presents Data on Lumateperone, ITI-214 and ITI-333 at the 56th Annual Meeti... - http://sbml.co/0ddc89a8",,,,938756429086969856,https://twitter.com/stockboardinc/status/938756429086969856
2017-12-07 13:05:05,CrweWorld,,0,0,0,"Intra-Cellular Therapies Presents Data on Lumateperone, ITI-214 and ITI-333 at the 56th Annual Meeting of the Americ ",,,,938756250011099136,https://twitter.com/CrweWorld/status/938756250011099136
2017-12-07 13:04:05,greenpenny2016,,0,0,0,"$ITCI - Intra-Cellular Therapies Presents Data on Lumateperone, ITI-214 and ITI-333 at the 56th Annual Meeting http://ih.advfn.com/p.php?pid=nmona&amp;article=76249686&amp;adw=1126416",,,,938755997568585728,https://twitter.com/greenpenny2016/status/938755997568585728
2017-11-27 13:55:29,medicalnewser,,0,0,0,"Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Treatment of Schizophrenia - http://www.medicalnewser.com/2017/11/27/intra-cellular-therapies-receives-fda-fast-track-designation-for-lumateperone-for-the-treatment-of-schizophrenia.html\",,,,935145051717586944,https://twitter.com/medicalnewser/status/935145051717586944
2017-11-22 15:00:05,PsychAnnals,,0,0,0,"The #FDA recently granted fast track designation to lumateperone for #schizophrenia Read more: http://bit.ly/2B0saSy #psychosis #pharma #psychiatry #MentalHealth",,,#FDA #schizophrenia #psychosis #pharma #psychiatry #MentalHealth,933349372145864704,https://twitter.com/PsychAnnals/status/933349372145864704
2017-11-22 13:04:06,SchizophrenNews,,0,0,0,"FDA grants fast track designation to lumateperone for schizophrenia #schizophrenia #bhive http://dld.bz/guZBe",,,#schizophrenia #bhive,933320183007055872,https://twitter.com/SchizophrenNews/status/933320183007055872
2017-11-21 21:30:21,Brian_Uberig,,0,0,0,"Intra-Cellular Therapies receives FDA Fast Track designation for Lumateperone for the treatment of Schizophrenia - ",,,,933085195032580102,https://twitter.com/Brian_Uberig/status/933085195032580102
2017-11-21 21:19:19,EMMAIntl,,0,0,0,"Intra-Cellular Therapies receives #FDA Fast Track designation for Lumateperone for the treatment of Schizoph... https://seekingalpha.com/news/3313478-intra-cellular-therapies-receives-fda-fast-track-designation-lumateperone-treatment?source=tweet $ITCI",,,#FDA,933082421695844353,https://twitter.com/EMMAIntl/status/933082421695844353
2017-11-21 19:30:03,StockGuruDotCom,,0,0,0,"Breaking Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Treatment of... http://tinyurl.com/ycyjslwm",,,,933054920827326465,https://twitter.com/StockGuruDotCom/status/933054920827326465
2017-11-20 23:08:40,MaisaCorp,,0,1,2,"$ITCI FDA Fast Track designation for lumateperone",,,,932747550007885826,https://twitter.com/MaisaCorp/status/932747550007885826
2017-11-20 22:06:10,SchizophrenNews,,0,0,0,"FDA Grants Fast Track Status to Lumateperone for Schizophrenia #schizophrenia #bhive http://dld.bz/guJaH",,,#schizophrenia #bhive,932731821535760384,https://twitter.com/SchizophrenNews/status/932731821535760384
2017-11-20 20:24:58,HottestStockNow,,0,0,0,"FDA Grants Fast Track designation for $ITCI 's lumateperone for the treatment of schizophrenia http://crweworld.com/article/news-provided-by-globenewswire/180763/intra-cellular-therapies-receives-fda-fast-track-designation-for-lumateperone-for-the-treatment-of-schizophrenia",,,,932706354975924227,https://twitter.com/HottestStockNow/status/932706354975924227
2017-11-20 16:38:04,TINMobileNews,,0,0,0,"Technical View: Intra-Cellular up on FDA Fast Track designation for lumateperone (The Fly) http://dlvr.it/Q1xxNQ",,,,932649253666635776,https://twitter.com/TINMobileNews/status/932649253666635776
2017-11-20 15:23:21,paynej247,,0,0,0,"$ITCI Up 6.33% PPS $16.29... *Intra-Cellular Therapies Receives FDA #FastTrack Designation for Lumateperone for the Treatment of Schizophrenia (Globe Newswire) ",,,#FastTrack,932630451495170049,https://twitter.com/paynej247/status/932630451495170049
2017-11-20 14:09:33,Ye_Olde_Finance,,0,0,0,"Intra-Cellular Therapies receives FDA Fast Track designation for Lumateperone for the treatment of Schizophrenia http://dlvr.it/Q1wlV9 #investing #news",,,#investing #news,932611880232763393,https://twitter.com/Ye_Olde_Finance/status/932611880232763393
2017-11-20 14:05:32,pharminews,,0,0,0,"Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone… https://goo.gl/fb/jk1zxf #news #pharma",,,#news #pharma,932610866444406784,https://twitter.com/pharminews/status/932610866444406784
2017-11-20 13:58:59,MarketCurrents,,0,1,1,"Intra-Cellular Therapies receives FDA Fast Track designation for Lumateperone for the treatment ... https://seekingalpha.com/news/3313478-intra-cellular-therapies-receives-fda-fast-track-designation-lumateperone-treatment?source=feed_f #premarket $ITCI",,,#premarket,932609219940958209,https://twitter.com/MarketCurrents/status/932609219940958209
2017-11-20 13:51:38,OpenOutcrier,,0,1,2,"$ITCI (+5.4% pre) Intra-Cellular Therapies Receives FDA Fast Track Des for Lumateperone for Schizophrenia - GN http://ooc.bz/l/18233",,,,932607370500411392,https://twitter.com/OpenOutcrier/status/932607370500411392
2017-11-20 13:42:34,STOCKWINNERScom,,0,0,0,"Intra-Cellular receives FDA Fast Track designation for lumateperone Intra-Cellular (ITCI) announced that the FDA... http://fb.me/2yrnJKHwO",,,,932605086420828160,https://twitter.com/STOCKWINNERScom/status/932605086420828160
2017-11-20 13:34:37,EvanRubinson,,0,0,0,"Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for Treatment of Schizophrenia $ITCI http://www.seekingalpha.com/article/17006894",,,,932603086840922112,https://twitter.com/EvanRubinson/status/932603086840922112
2017-11-20 13:04:11,SchizophrenNews,,0,0,0,"Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Tr.. #schizophrenia #bhive http://dld.bz/guBUx",,,#schizophrenia #bhive,932595427303714817,https://twitter.com/SchizophrenNews/status/932595427303714817
2017-11-20 12:23:06,Datamonitor_SY,,0,0,0,"FDA grants Intra-Cellular Therapies’ schizophrenia drug, lumateperone, fast track designation based on its exceptional potential to fulfil critical unmet need for better-tolerated antipsychotics ",,,,932585087434153984,https://twitter.com/Datamonitor_SY/status/932585087434153984
2017-11-20 12:15:42,StockGuruDotCom,,0,0,0,"Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Treatment of Schizophrenia https://stockguru.com/2017/11/20/intra-cellular-therapies-receives-fda-fast-track-designation-for-lumateperone-for-the-treatment-of-schizophrenia/",,,,932583228879331329,https://twitter.com/StockGuruDotCom/status/932583228879331329
2017-11-20 12:08:41,trickmitch1,,0,0,0,"Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Treatment... $ITCI https://pro.benzinga.com @benzinga",,@Benzinga,,932581462229991424,https://twitter.com/trickmitch1/status/932581462229991424
2017-11-20 12:05:58,odibro,,0,2,3,"$ITCI Receives FDA Fast Track Designation for Lumateperone for the Treatment of Schizophrenia",,,,932580775555489792,https://twitter.com/odibro/status/932580775555489792
2017-11-20 12:05:38,stockboardinc,,0,0,0,"$ITCI Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Treatment of S... - http://sbml.co/2381290a",,,,932580693900779520,https://twitter.com/stockboardinc/status/932580693900779520
2017-11-20 12:03:41,financialbuzz,,0,0,0,"Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Treatment of Schizophrenia http://financialbuzz.com/intra-cellular-therapies-receives-fda-fast-track-designation-for-lumateperone-for-the-treatment-of-schizophrenia-938340",,,,932580204756713472,https://twitter.com/financialbuzz/status/932580204756713472
2017-11-20 12:03:23,krunox123,,0,0,0,"Intra-Cellular Therapies Receives FDA Fast Track Designation for Lumateperone for the Treatment of Schizophrenia http://ift.tt/2mL6s2m",,,,932580125824225281,https://twitter.com/krunox123/status/932580125824225281
2017-11-20 12:02:28,stocknewsdotcom,,0,0,0,"$ITCI Receives FDA Fast Track Designation for Lumateperone for the Treatment of Schizophrenia https://stocknews.com/news/itci-receives-fda-fast-track-designation-for-lumateperone-for-the-treatment/",,,,932579896710303745,https://twitter.com/stocknewsdotcom/status/932579896710303745
2017-11-20 12:00:37,BioStocks,,0,0,1,"$ITCI Receives FDA Fast Track Designation for Lumateperone for the Treatment of Schizophrenia",,,,932579432073588736,https://twitter.com/BioStocks/status/932579432073588736
2017-11-15 07:39:43,HottestStockNow,,0,0,0,"$ITCI Reveals findings related to its lumateperone and ITI-214 development programs ",,,,930701835861708801,https://twitter.com/HottestStockNow/status/930701835861708801
2017-11-14 16:06:36,into_AI,,0,0,0,"nts Data on Mechanism of Action of Lumateperone and ITI-214 at the … - https://homeai.info/blog/news-stories/intra-cellular-therapies-presents-data-on-mechanism-of-action-of-lumateperone-and-iti-214-at-the-2/ #neuroscience",,,#neuroscience,930467005995593728,https://twitter.com/into_AI/status/930467005995593728
2017-11-14 14:46:03,into_AI,,0,0,0,"nts Data on Mechanism of Action of Lumateperone and ITI-214 at the … - http://homeai.info/blog/news-stories/intra-cellular-therapies-presents-data-on-mechanism-of-action-of-lumateperone-and-iti-214-at-the/ #neuroscience",,,#neuroscience,930446736304279552,https://twitter.com/into_AI/status/930446736304279552
2017-11-14 13:54:39,financialbuzz,,0,0,0,"Intra-Cellular Therapies Presents Data on Mechanism of Action of Lumateperone and ITI-214 at the 2017 Society fo.. http://financialbuzz.com/intra-cellular-therapies-presents-data-on-mechanism-of-action-of-lumateperone-and-iti-at-the-society-for-neuroscience-sfn-annual-meeting-933117",,,,930433801896914945,https://twitter.com/financialbuzz/status/930433801896914945
2017-11-14 13:05:24,stockboardinc,,0,0,0,"$ITCI Intra-Cellular Therapies Presents Data on Mechanism of Action of Lumateperone and ITI-214 at the 201... - http://sbml.co/ab68f70d",,,,930421406025777152,https://twitter.com/stockboardinc/status/930421406025777152
2017-11-14 13:04:12,odibro,,0,0,3,"$ITCI Presents Data on Mechanism of Action of Lumateperone and ITI-214 at the #SfN17 https://globenewswire.com/news-release/2017/11/14/1185813/0/en/Intra-Cellular-Therapies-Presents-Data-on-Mechanism-of-Action-of-Lumateperone-and-ITI-214-at-the-2017-Society-for-Neuroscience-SfN-Annual-Meeting.html",,,#SfN17,930421103377477632,https://twitter.com/odibro/status/930421103377477632
2017-11-14 13:01:38,krunox123,,0,0,0,"Intra-Cellular Therapies Presents Data on Mechanism of Action of Lumateperone and ITI-214 at the 2017 Society for … http://ift.tt/2z1GtcP",,,,930420460810067968,https://twitter.com/krunox123/status/930420460810067968
2017-11-13 06:10:17,RoccoLefkowitz,RoccoLefkowitz,0,0,1,"$ITCI's below market financing cost them all the momentum they gained in Aug/Sept from progressing their lumateperone NDA timeline. I've done well from this level before and I think enterprise value is pretty low for prospects so I'll likely be adding soon, BioTwitter be damned. ",,,,929954552685752320,https://twitter.com/RoccoLefkowitz/status/929954552685752320
2017-10-16 02:54:30,j_pennett,,0,0,0,"Intra-Cellular Therapies raised $150M #funding to prepare for an @US_FDA filing for lead drug Lumateperone in #schizophrenia next year",,@US_FDA,#funding #schizophrenia,919758421557047296,https://twitter.com/j_pennett/status/919758421557047296
2017-09-12 22:00:59,PsychAnnals,,0,0,0,"Switching to lumateperone improved weight gain,#schizophrenia symptoms &amp; other cardiometabolic outcomes. Study: http://bit.ly/2wZcKil",,,,907725753701294085,https://twitter.com/PsychAnnals/status/907725753701294085
2017-09-12 21:26:00,GoHealio,,0,0,0,"Switching to lumateperone improved weight gain,#schizophrenia symptoms &amp; other cardiometabolic outcomes. Study: http://bit.ly/2wZcKil",,,,907716952747016192,https://twitter.com/GoHealio/status/907716952747016192
2017-09-12 20:03:13,induspsych,,0,0,0,"Switching to lumateperone improves weight gain, schizophrenia symptoms #Psychiatry http://dld.bz/geDm4",,,#Psychiatry,907696120444399618,https://twitter.com/induspsych/status/907696120444399618
2017-09-08 13:03:11,SchizophrenNews,,0,0,0,"Intra-Cellular Therapies (ITCI): More Positive Progress For Lumateperone - BTIG #schizophrenia #bhive http://dld.bz/gdXhp",,,#schizophrenia #bhive,906140862358355968,https://twitter.com/SchizophrenNews/status/906140862358355968
2017-09-08 12:41:48,_B_I_O_T_E_C_H_,,0,1,0,"BTIG $ITCI Supportive New Data, Tox Question Satisfied, More Indications for Lumateperone—Target to $36",,,,906135479346765824,https://twitter.com/_B_I_O_T_E_C_H_/status/906135479346765824
2017-09-08 11:31:53,AnalystWire,,0,0,0,"Intra-Cellular Therapies $ITCI: More Positive Progress For Lumateperone - BTIG ",,,,906117884665049089,https://twitter.com/AnalystWire/status/906117884665049089
2017-09-08 00:55:54,JPMGGA,,0,1,0,"$ITCI announces positive topline data with Lumateperone in patients with Schizophrenia. Next PT $25, $30, then $35 $XBI $IBB #Trade2017",,,#Trade2017,905957835879587840,https://twitter.com/JPMGGA/status/905957835879587840
2017-09-07 23:33:13,MaisaCorp,,0,0,1,"$IPCI positive topline data from the first part of an open-label safety switching study with lumateperone in patients with schizophrenia.",,,,905937025949462529,https://twitter.com/MaisaCorp/status/905937025949462529
2017-09-07 17:52:08,investpro2000,,0,0,0,"Intra-Cellular Therapies announces positive topline data from safety switching study with Lumateperone in p... https://seekingalpha.com/news/3294106-intra-cellular-therapies-announces-positive-topline-data-safety-switching-study-lumateperone?source=tweet $ITCI",,,,905851190856085507,https://twitter.com/investpro2000/status/905851190856085507
2017-09-07 13:20:04,StocksThatGo,,0,0,0,"ALERT: NEWS $ITCI Positive Topline Data From 6-Week Open-label Safety Switching Study with Lumateperone in Patients with Schizophrenia",,,,905782725176590336,https://twitter.com/StocksThatGo/status/905782725176590336
2017-09-07 13:04:31,7LadyQ,,0,0,1,"$ITCI Intra-Cellular Therapies announces positive topline data from safety switching study with Lumateperone in patients with Schizophrenia",,,,905778808061661184,https://twitter.com/7LadyQ/status/905778808061661184
2017-09-07 12:23:42,lifeoncoin,,0,0,0,"""BRIEF-Intra-Cellular Therapies ‍announces positive topline data with Lumateperone"" ",,,,905768537901424641,https://twitter.com/lifeoncoin/status/905768537901424641
2017-09-07 12:21:36,beeznescom,,0,0,0,"BRIEF-Intra-Cellular Therapies ‍announces positive topline data with Lumateperone http://reut.rs/2gOK5qd #BusinessNews #Companies",,,#BusinessNews #Companies,905768010400636928,https://twitter.com/beeznescom/status/905768010400636928
2017-09-07 12:21:11,NTKRNow,,0,0,0,"BRIEF-Intra-Cellular Therapies ‍announces positive topline data with Lumateperone http://ift.tt/2gKgxqo",,,,905767902648913920,https://twitter.com/NTKRNow/status/905767902648913920
2017-09-07 12:19:12,nycsocialg,,0,0,0,"BRIEF-Intra-Cellular Therapies ‍announces positive topline data with Lumateperone ",,,,905767407440015361,https://twitter.com/nycsocialg/status/905767407440015361
2017-09-07 11:04:04,odibro,,0,5,0,"$ITCI Positive Topline Data From 6-Week Open-label Safety Switching with Lumateperone in Pats with Schizophrenia ",,,,905748496057327618,https://twitter.com/odibro/status/905748496057327618
2017-09-07 11:04:03,Trader_gurl,,0,0,0,"$ITCI Positive Data From 6-Week Open-label Safety Switching Study with Lumateperone in Patients with Schizophrenia https://globenewswire.com/news-release/2017/09/07/1113925/0/en/Intra-Cellular-Therapies-Announces-Positive-Topline-Data-From-6-Week-Open-label-Safety-Switching-Study-with-Lumateperone-in-Patients-with-Schizophrenia.html",,,,905748495310745602,https://twitter.com/Trader_gurl/status/905748495310745602
2017-09-07 11:01:16,BioStocks,,0,2,0,"$ITCI Announces Positive Topline Data From 6-Week Open-label Safety Switching Study with Lumateperone in Patients with Schizophrenia",,,,905747792840273920,https://twitter.com/BioStocks/status/905747792840273920
2017-09-07 11:01:05,d4ytrad3,,0,0,0,"$ITCI Announces Positive Topline Data From 6-Week Open-label Safety Switching Study with Lumateperone in Patients with Schizophrenia",,,,905747748238086144,https://twitter.com/d4ytrad3/status/905747748238086144
2017-08-30 20:25:01,cryoport,,0,1,1,"$CYRX client Intra-Cellular Therapies $ITCI plans to submit lumateperone of ITI-007-301 study for @US_FDA approval. http://bit.ly/2vcNENi",,@US_FDA,,902990563527598085,https://twitter.com/cryoport/status/902990563527598085
2017-08-27 19:43:01,BioPharmaDive,,0,0,0,"Intra-Cellular expects to submit an NDA for lumateperone (also known as ITI-007) in mid-2018 http://bit.ly/2v5INgY $ITCI",,,,901892827369668609,https://twitter.com/BioPharmaDive/status/901892827369668609
2017-08-24 17:31:05,jjgiablue,,0,0,0,"$ITCI-JMP upgrades to buy PT=$24 (sh price=$15). Sees NT results for lumateperone as restoring confidence in efficacy, de-risk FDA approval.",,,,900772463352528896,https://twitter.com/jjgiablue/status/900772463352528896
2017-08-24 15:29:39,RoccoLefkowitz,RoccoLefkowitz,0,0,0,"Didn't have the guts to double down before the lumateperone update, now I'll just see where $ITCI levels out before selling.",,,,900741904563916801,https://twitter.com/RoccoLefkowitz/status/900741904563916801
2017-08-24 14:22:30,BioWorld,,0,0,0,"$ITCI 'unpawsed' and safety trial moves ahead as FDA signs off re dog data with lumateperone http://bit.ly/2w1rIUv",,,,900725006195449860,https://twitter.com/BioWorld/status/900725006195449860
2017-08-23 21:42:49,fwpharma,,0,0,0,"Intra-Cellular unveils plans to submit lumateperone for US approval next year following FDA update http://bit.ly/2wzgW9d #FDA #pharma",,,#FDA #pharma,900473427777257472,https://twitter.com/fwpharma/status/900473427777257472
2017-08-23 21:12:00,BioPharmaDive,,0,3,3,"Intra-Cellular expects to submit an NDA for lumateperone (also known as ITI-007) in mid-2018 http://bit.ly/2v5INgY $ITCI",,,,900465672894939136,https://twitter.com/BioPharmaDive/status/900465672894939136
2017-08-23 20:25:59,investpro2000,,0,0,0,"Intra-Cellular gets good news from FDA related to toxicity of lumateperone; shares ahead 33% premarket https://seekingalpha.com/news/3291224-intra-cellular-gets-good-news-fda-related-toxicity-lumateperone-shares-ahead-33-percent?source=tweet $ITCI",,,,900454090823667716,https://twitter.com/investpro2000/status/900454090823667716
2017-08-23 15:38:58,AngelaStrongSCT,,0,1,0,"#Intra-Cellular gets go-ahead from #FDA for its #Neuropsychiatric Disease drug #lumateperone http://www.biopharmadive.com/news/intra-cellular-fda-lumateperone-nda-toxicology-study/503311/?utm_source=Sailthru&amp;utm_medium=email&amp;utm_campaign=Issue:%202017-08-23%20BioPharma%20Dive%20%5Bissue:11704%5D&amp;utm_term=BioPharma%20Dive via @BioPharmaDive",,@BioPharmaDive,#Intra #FDA #Neuropsychiatric #lumateperone,900381862597668864,https://twitter.com/AngelaStrongSCT/status/900381862597668864
2017-08-23 13:24:20,STOCKWINNERScom,,0,0,0,"Intra-Cellular says to move forward with lumateperone long-term safety study Intra-Cellular Therapies (ITCI)... http://fb.me/3JBpjztZz",,,,900347977973194752,https://twitter.com/STOCKWINNERScom/status/900347977973194752
2017-08-23 13:00:16,NTKRNow,,0,0,0,"Intra-Cellular gets good news from FDA related to toxicity of lumateperone; shares ahead 33% premarket http://ift.tt/2irX6Xw",,,,900341921561706497,https://twitter.com/NTKRNow/status/900341921561706497
2017-08-23 12:53:29,7LadyQ,,0,0,0,"$ITCI Intra-Cellular gets good news from FDA related to toxicity of lumateperone; shares ahead 33% premarket",,,,900340216434765826,https://twitter.com/7LadyQ/status/900340216434765826
2017-08-23 12:52:16,wlstcom,,0,0,0,"Intra-Cellular gets good news from FDA related to toxicity of lumateperone; shares ahead 33% premarket #premarket https://seekingalpha.com/news/3291224-intra-cellular-gets-good-news-fda-related-toxicity-lumateperone-shares-ahead-33-percent",,,#premarket,900339909906518018,https://twitter.com/wlstcom/status/900339909906518018
2017-08-23 12:52:11,MarketCurrents,,0,2,1,"Intra-Cellular gets good news from FDA related to toxicity of lumateperone; shares ahead 33% pre... https://seekingalpha.com/news/3291224-intra-cellular-gets-good-news-fda-related-toxicity-lumateperone-shares-ahead-33-percent?source=feed_f #premarket $ITCI",,,#premarket,900339889484382208,https://twitter.com/MarketCurrents/status/900339889484382208
2017-08-23 12:14:00,DonnaYoungDC,,0,1,1,"Post-#FDA interaction, $ITCI moving forward w/ long-term lumateperone safety study/preparing NDA by mid-2018 http://globenewswire.com/news-release/2017/08/23/1091441/0/en/Intra-Cellular-Therapies-Announces-Positive-Regulatory-Update-On-Schizophrenia-Program.html #pharma",,,#FDA #pharma,900330278748606464,https://twitter.com/DonnaYoungDC/status/900330278748606464
2017-08-09 18:24:11,RoccoLefkowitz,,0,0,0,"$ITCI just isn't worth the risk until there's resolution with FDA regarding potential toxicity of lumateperone",,,,895350008337371147,https://twitter.com/RoccoLefkowitz/status/895350008337371147
2017-05-19 19:30:03,cryoport,,0,0,0,"Data from $CYRX client $ITCI shows potential for potent &amp; rapid #antidepressant effects with Lumateperone. http://bit.ly/2r1xGjz #bipolar",,,#antidepressant #bipolar,865650779448778753,https://twitter.com/cryoport/status/865650779448778753
2017-05-10 12:07:01,QLFilings,,0,0,0,"$ITCI filed Form 8-K with the SEC. Most mentioned words: lumateperone, clinical, financial, development, including",,,,862277796143476736,https://twitter.com/QLFilings/status/862277796143476736
2017-05-08 11:50:21,nycsocialg,,0,0,0,"BRIEF-Intra-Cellular says presents data supporting potential for antidepressant activity with lumateperone ",,,,861548823881146368,https://twitter.com/nycsocialg/status/861548823881146368
2017-05-08 11:48:18,lifeoncoin,,0,0,0,"""BRIEF-Intra-Cellular says presents data supporting potential for antidepressant activity with lumateperone"" ",,,,861548309445562368,https://twitter.com/lifeoncoin/status/861548309445562368
2017-05-08 11:05:03,krunox123,,0,0,0,"Intra-Cellular Therapies Presents Data Supporting the Potential for Potent and Rapid Antidepressant Activity with Lumateperone …",,,,861537427487416321,https://twitter.com/krunox123/status/861537427487416321
2017-05-04 13:20:17,CBPartners,,0,0,0,"#FDA safety concerns over antipsychotic LUMATEPERONE cut $ITCI #MarketCap by ~a quarter",,,#FDA #MarketCap,860121905038229504,https://twitter.com/CBPartners/status/860121905038229504
2017-05-04 12:40:18,CBPartners,,0,1,0,"#FDA requests more data on $ITCI antipsychotic LUMATEPERONE questioning possible long-term exposure issues in humans http://bit.ly/2pHM7Lg",,,#FDA,860111842563301377,https://twitter.com/CBPartners/status/860111842563301377
2017-05-01 16:08:11,fwpharma,,0,0,1,"FDA requests more information on studies for Intra-Cellular's proposed schizophrenia drug lumateperone ",,,,859076996420304896,https://twitter.com/fwpharma/status/859076996420304896
2017-05-01 12:33:11,drfranktarazi,,0,0,0,"#FDA delays filing of $ITCI #lumateperone for #schizophrenia! Long-term safety concerns! Earliest to file mid 2018! $ITCI crushed down &gt;40%!",,,#FDA #lumateperone #schizophrenia,859022891312140289,https://twitter.com/drfranktarazi/status/859022891312140289
2017-03-01 12:46:24,contixalerts,,0,0,0,"$ITCI FDA meeting late mar to discuss NDA submission for lumateperone @zbiotech https://app.contix.com/Free-Trial/35963471",,@zbiotech,,836920557899763713,https://twitter.com/contixalerts/status/836920557899763713
2017-03-01 12:45:55,zbiotech,,0,1,2,"$ITCI FDA meeting late mar to discuss NDA submission for lumateperone",,,,836920432607571968,https://twitter.com/zbiotech/status/836920432607571968
2016-12-06 21:12:44,investpro2000,,0,1,2,"$ITCI Pooled Analyses May Illuminate lumateperone Efficacy, &amp; Possible Path Forward $22 target by Charles C. Duncan, PhD, Piper Jaffray",,,,806245009297174529,https://twitter.com/investpro2000/status/806245009297174529
2016-10-27 19:54:07,CNSSummit,,0,0,2,"LIVE #CNSSummit Kimberly Vanover-IntraCellular Therapeutics-shares lumateperone program in schizophrenia &amp; discusses placebo response issues",,,#CNSSummit,791729710896128000,https://twitter.com/CNSSummit/status/791729710896128000
2016-10-27 19:53:48,Innov_Clin_Neur,,0,0,0,"LIVE #CNSSummit Kimberly Vanover-IntraCellular Therapeutics-shares lumateperone program in schizophrenia &amp; discusses placebo response issues",,,#CNSSummit,791729630617231364,https://twitter.com/Innov_Clin_Neur/status/791729630617231364
2016-05-18 07:56:16,MedChemExpress,,0,0,0,"Lumateperone Tosylate is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2... http://www.medchemexpress.com/lumateperone-Tosylate.html",,,,732842225621684224,https://twitter.com/MedChemExpress/status/732842225621684224
